Under the patronage of

Committees

Honorary Presidents
C Black, S Jablonska,
F Wollheim, T Medsger

Steering Committee
DE Furst, M Matucci–Cerinic, A Tyndall,
U Mueller–Ladner, L Guillevin, K Takehara,
J Seibold and the following Chairpersons:

1. Chairpersons of the Abstract Committee:
   **O Distler, P Sampaio Barros**
2. Chairpersons of the Clinical Committee:
   **Y Allanore, D Khanna**
3. Chairpersons of the Basic Committee:
   **J Varga, J Distler**
4. Chairperson of the Workshops:
   **P Clements**
5. Liaison officer with the Scleroderma Workshop:
   **C Denton, R Lafyatis**
6. Chairpersons of the Mentoring Programme:
   **L Czirjak, M Mayes**

Scientific Committee
D Abraham, M Baron, P Carreira, M Cutolo,
N Darmjanov, F Del Galdo, J Distler, A Gabrielli, S Gay,
R Giacomelli, E Hachulla, A Herrick, M Inanc,
B Kahaleh, R Knobler, O Kowal–Bielecka, T Krieg,
M Kuwana, MT Li, P Merkel, J Pope, S Rednic,
G Riemekasten, S Sato, J Scali, Y Shoenfeld, R Silver,
V Steen, R Simms, M Trojanowska, G Valentini, F van
den Hoogen, J van Laar, U Walker, A Wells, F Wigley

FESCA Board
A Tyrrell Kennedy, President
B Garay–Toth, Vice–President
D Demetriou–Charalambous, Treasurer
Alexandra Portales, Secretary
C Van den Bosch, Legal Advisor
THURSDAY, FEBRUARY 6

13:30–16:45  Pre-Meeting workshops
   See program at page 9

17:00–18:00  Satellite Symposia
   See program at page 12

18:15  Welcome from LEPTIS MAGNA ROOM
   the World Scleroderma Foundation

18:30  Welcome from LEPTIS MAGNA ROOM
   the Patron
   of the World Scleroderma Foundation
   The impact of scleroderma on a creative genius
   A. Klee (CH)

18.45-19.00  Welcome from LEPTIS MAGNA ROOM
   the Patients’ Representative
   The Patients’ Perspective
   A Kennedy (IRL), President of FESCA

19:00-19:40  Opening Lectures
   LEPTIS MAGNA ROOM
   Two-years in Review-What’s new since
   Madrid: the Cutting Edge
   Chairpersons: C Black (UK), F Wollheim (S)

19:00  The clinical overview
   M Matucci-Cerinic (I)

19:20  The basic and translational overview
   J Varga (USA)

19:40  Rome Video

20:00  Light welcome cocktail
08:00–09:20 **Session 1**

**Management and assessment of newly diagnosed SSc**

Chairpersons: J van Laar (UK), N Damjanov (SR)

08:00 What to do for a patient with newly diagnosed SSc
  - How to assess a patient with new onset of possible systemic sclerosis
  - What are the standard of care tests in early SSc patient
  - What are the baseline factors of poor prognosis in very early and early SSc
  
P Clements (USA)

Chairpersons: F Van den Hoogen (NL), S Johnson (CAN)

08:20 NEW EULAR/ACR CLASSIFICATION CRITERIA FOR SYSTEMIC SCLEROSIS IN CLINICAL PRACTICE
  
O Distler et al (CH)

08:30 2013 CLASSIFICATION CRITERIA FOR SYSTEMIC SCLEROSIS AN AMERICAN COLLEGE OF RHEUMATOLOGY/EUROPEAN LEAGUE AGAINST RHEUMATISM COLLABORATIVE INITIATIVE.
  
J Pope et al (CAN)

08:40 PERFORMANCE OF THE OLD 1980 ACR AND THE NEW ACR–EULAR SYSTEMIC SCLEROSIS (SSC) CLASSIFICATION CRITERIA IN PATIENTS WITH LIMITED CUTANEOUS SSC
  
P Carreira et al (E)

08:50 EARLY ACCRUAL OF ORGAN DAMAGE IN SCLERODERMA: RATIONALE FOR DERIVATION AND VALIDATION OF A DISEASE DAMAGE INDEX IN SYSTEMIC SCLEROSIS
  
T Tay et al (AUS)

09:00 PERFORMANCE OF THE 2013 ACR/EULAR CLASSIFICATION CRITERIA FOR SYSTEMIC SCLEROSIS IN A SINGLE CENTER SETTING
  
R Dobrota et al (R)

09:10 SSC INTRINSIC SUBSET CLASSIFICATION IN PATIENTS THAT DEMONSTRATE CLINICAL IMPROVEMENT DURING TREATMENT
  
M Whitfield et al (USA)

09:20–10:10 **Session 2**

**Miscellaneous and differential diagnosis of SSc**

Chairpersons: U Walker (CH), R Silver (USA)

09:20 How to differentiate SSc from scleroderma-like disorder?
  - Criteria for very early and early diagnosis of SSc
  - Differential diagnoses to be presented including IgG4 syndromes, Shulman, nephrogenic fibrosis, borreliosis
  
A Tyndall (CH)

09:40 GENDER EFFECTS ON SYSTEMIC SCLEROSIS PHENOTYPE: A LONGITUDINAL EUSTAR STUDY BASED ON MORE THAN 10 000 PATIENTS
  
M Elhai et al (F)

09:50 EPIDEMIOLOGY OF CANCER IN SYSTEMIC SCLEROSIS. SYSTEMATIC REVIEW AND META–ANALYSIS OF CANCER INCIDENCE, PREDICTORS AND MORTALITY
  
S Johnson et al (CAN)

10:00 JOINT AND TENDON INVOLVEMENT PREDICT SEVERE DISEASE PROGRESSION IN SYSTEMIC SCLEROSIS: A EUSTAR PROSPECTIVE STUDY
  
J Avouac et al (F)

10:10–10:30 COFFEE BREAK
10:30–11:00 **Session 3**
**LEPTIS MAGNA ROOM**

**The great debate**
Chairpersons: R Giacomelli (I), B Maurer (CH)

The place of Corticosteroids in SSc
T Medsger (USA), J Seibold (USA)

11:00–12:00 **Poster tours**

**Clinical**
Poster tour 1: Raynaud & Ulcers - V Riccieri (I)
PS01 to PS06

Poster tour 2: Raynaud & Ulcers - E Rosato (I)
PS07 to PS12

Poster tour 3: Pulmonary / Interstitial Lung Disease - I H Tarner (D)
PS13 to PS19

Poster tour 4: Pulmonary Arterial Hypertension
D Launay (F)
PS20 to PS27

Poster tour 5: Cardiac - A Vacca (I)
PS28 to PS34

Poster tour 6: Outcomes, quality of life, psychological & social - P Carreira (E)
PS35 to PS41

Poster tour 7: Imaging - F Cozzi (I)
PS42 to PS48

Poster tour 8: Therapy/Miscellaneous - A Sulli (I)
PS49 to PS55

Poster tour 9: Musculoskeletal system & rehabilitation - P Ostojic (SRB)
PS56 to PS61

Poster tour 10: Upper and Lower Gastrointestinal/ nutrition - T Minier (H)
PS62 to PS68

Poster tour 11: Pregnancy & sexual problems
L Saketkoo (USA)
PS69 to PS73

Poster tour 12: Therapy - S Bellando-Randone (I)
PS74 to PS82

**Basic**
Poster tour 13: Pathogenesis - M Manetti (I)
PS83 to PS94

Poster tour 14: Pathogenesis - GL Moroncini (I)
PS95 to PS102

Poster tour 15: Pathogenesis - S Assassi (USA)
PS103 to PS111

12:00–13:30 **Satellite Symposia**
See program at page 11

13:30–14:30 **Working lunch**
LEVEL –2

14:30–15:30 **Satellite Symposia**
See program at page 11

15:30–16:40 **Concurrent Sessions**

15:30–16:30 **Concurrent Session 4**
**LEPTIS MAGNA ROOM**

An integrated approach to gastro–intestinal involvement
Chairpersons: A Herrick (UK), T Frech (USA)

15:30 Gl: How to evaluate, diagnose and treat upper and lower Gl involvement
U Mueller–Ladner (D)
15:50  New therapeutic approaches  
       C Murray (UK)

16:10  MORTALITY, RECURRENCE, AND HOSPITAL COURSE OF PATIENTS WITH SYSTEMIC SCLEROSIS RELATED ACUTE INTESTINAL PSEUDO–OBSTRUCTION  
       C Derk et al (USA)

16:20  PREVALENCE, CORRELATES AND OUTCOMES OF GASTRIC ANTRAL VASCULAR ECTASIA IN SYSTEMIC SCLEROSIS: A EUSTAR CASE–CONTROL STUDY  
       E Ghranassia et al (F)

15:30–16:40  Concurrent Session 5  
 MASSALIA ROOM  
 Links to inflammation, immunity and vascular disease  
 Chairpersons: J Distler (D), D Abraham (UK)

15:30  Immunological mechanisms of fibrosis  
       T Wynn (USA)

15:50  PIGMENT EPITHELIUM DERIVED FACTOR SECRETED BY SSC FIBROBLASTS INHIBITS ANGIO AND VASCULOGENESIS IN VITRO  
       V Liakouli et al (I)

16:00  SCLERODERMA DERMAL FIBROBLASTS OVEREXPRESS VASCULAR ENDOTHELIAL GROWTH FACTOR DUE TO AUTOCRINE TRANSFORMING GROWTH FACTOR BETA SIGNALING  
       I Kajihara et al (JPN)

16:10  IL 6 TRANS–SIGNALLING AND CCL2 CO–REGULATE FIBROBLAST DEPENDENT TRANS–ENDOTHELIAL MIGRATION OF MONONUCLEAR CELLS AND FIBROTIC RESPONSE IN SCLERODERMA  
       R Alade et al (UK)

16:20  THE GLOBAL MICRORNA PROFILE OF SKIN IN SYSTEMIC SCLEROSIS  
       G Salazar et al (USA)

16:30  THE PRESENCE OF A COLD TEMPERATURE SENSOR IN THE VASCULAR ENDOTHELium: ENHANCED EXPRESSION IN SSC SKIN AND ENDOTHELIAL CELLS DYSFUNCTION AFTER ACTIVATION  
       B Kahaleh et al (USA)

16:40–16:55  COFFEE BREAK

16:55–18:15  Concurrent Sessions

16:55–17:25  Concurrent Session 6  
 LEPTIS MAGNA ROOM  
 Biologics and novel therapies in SSc  
 Chairpersons: R Simms (USA), C Beyer (D)

16:55  Use of biologics in SSc–indications and future perspective  
       – An update on the use of biologics in SSc  
       – Benefit/risk ratio of the main molecules  
       – Upcoming trials  
       Y Allanore (F)

17:25–17:55  Concurrent Session 7  
 LEPTIS MAGNA ROOM  
 Treatment and DMARDS in SSc  
 Chairpersons: P Sampaio Barros (BRA), M Kuwana (JPN)

17:25  How to treat rapidly progressive SSc  
       C Denton (UK)

16:55–18:15  Concurrent Session 8  
 MASSALIA ROOM  
 Mechanism of fibrosis  
 Chairpersons: A Gabrielli (I), R Lafyatis (USA)

16:55  Biomechanical Signaling of Myofibroblast Activation  
       V Thannickal (USA)

17:15  SIGNAL TRANSDUCER AND ACTIVATOR OF RANSRIPTION3 (STAT3) REGULATES TRANSFORMING GROWTH FACTOR–BETA INDUCED FIBROSIS IN SYSTEMIC SCLEROSIS  
       B Sumova et al (D)
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>17:25</td>
<td>17:25</td>
<td>INVESTIGATING THE ROLE OF MYOCARDIN RELATED TRANSCRIPTION FACTOR (MRTF) IN SYSTEMIC SCLEROSIS</td>
<td>X Shiwen et al (UK)</td>
</tr>
<tr>
<td>17:35</td>
<td>17:35</td>
<td>EPHRIN B2 IS OVEREXPRESSED IN HUMAN SCLERODERMA SKIN AND MEDIATES FIBROBLAST TO MYOFIBROBLAST DIFFERENTIATION, AND INDUCES FIBROSIS IN MICE</td>
<td>M Kapoor et al (CAN)</td>
</tr>
<tr>
<td>17:45</td>
<td>17:45</td>
<td>EXPERIMENTAL RENAL INJURY IN A TGFBETA DEPENDENT MOUSE MODEL OF SCLERODERMA</td>
<td>E Derrett-Smith et al (UK)</td>
</tr>
<tr>
<td>17:55</td>
<td>17:55</td>
<td>DIRECT THROMBIN INHIBITOR DABIGATRAN ETEXILATE PROTECTS ALVEOLAR EPITHELIAL CELLS FROM APOPTOSIS IN A BLEOMYCIN MODEL OF SCLERODERMA-ASSOCIATED INTERSTITIAL LUNG DISEASE</td>
<td>G Bogatkevich et al (USA)</td>
</tr>
<tr>
<td>18:05</td>
<td>18:05</td>
<td>STIMULATION OF THE SOLUBLE GUANYLATE CYCLASE (SGC) INHIBITS DERMAL FIBROSIS BY BLOCKING NON-CANONICAL TGFBETA-SIGNALING</td>
<td>C Beyer et al (D)</td>
</tr>
</tbody>
</table>

**SATURDAY, FEBRUARY 8**

**08:00–09:00 Session 9**

*Meet the Professors session*

See information at page: 42

- Approach to SSc–Related Cardiac Disease
  L Czirjak (H) & Y Allanore (F)

- Approach to Kidney Management
  L Guillevin (F) & C Denton (UK)

**09:00–09:40 Session 10**

*Cardiovascular involvement*

Chairpersons: M Inanc (TR), A Vacca (I)

- Conduction and Rhythm defects in scleroderma
  C Meune (F)

- Improvement of digital ulcerative disease in patients with systemic sclerosis is associated with better functional prognosis
  L Mouthon et al (F)

**09:40–10:30 Session 11**

*Interstitial lung disease*

Chairpersons: B Kahaleh (USA), O Kowal Bielecka (Pl)

- SSc–ILD: Who to treat and how to treat?
  - Discuss natural history and disease progression in ILD
  - How to identify patients who require immuno suppressive therapy
  - Efficient drugs and predictors of response
  D. Khanna (USA)
10:00 Progressive deterioration of patients with scleroderma with pulmonary involvement: 11-year outcomes from the Scleroderma Lung Study (SLS1)
K Sullivan et al (USA)

S Johnson et al (CAN)

10:20 Genetic markers of susceptibility and interstitial lung disease in systemic sclerosis patients: an Immunochip study
L Bossini–Castillo et al (E)

10:30–10:45 Coffee Break

10:45–11:55 Session 12
Leptis Magna Room
Pulmonary Arterial Hypertension
Chairpersons: V Steen (USA), E Hachulla (F)

10:45 PAH: How to make the right diagnosis at the right time
- Risk factors and predictors of PAH
- Criteria guiding the clinician to refer the patient for catheterisation
- How to interpret catheterisation
O Distler (CH)

Chairpersons: M Hinchcliff (USA), L Chung (USA)

11:05 Characteristics of systemic sclerosis patients with pulmonary hypertension and a pulmonary capillary wedge pressure >15 in the Pharos registry
L Saketkoo et al (USA)

11:15 Recommendations for screening and detection of connective tissue disease associated pulmonary arterial hypertension
D Khanna et al (USA)

11:25 A comparison of the predictive accuracy of three screening models (DETECT V. ESC/ERS V. ASIG) for pulmonary arterial hypertension in systemic sclerosis
Y J Hao et al (AUS)

11:35 Clinical subtype and autoantibodies both help predict pulmonary arterial hypertension but autoantibodies are stronger predictors of developing secondary pulmonary hypertension
R Domsic et al (USA)

11:45 Prognostic value of NT–ProBNP in systemic sclerosis patients without pulmonary hypertension
M Antivalle et al (I)

11:55–12:10 Special Lecture
Leptis Magna Room
Chairpersons: F Del Galdo (UK), G Riemekasten (D)

DeSScipher, a jump in the future!
U Mueller-Ladner (D)

12:10–12.30 Summary of the congress
Leptis Magna Room
Chairperson: L Guillevin (F)

Highlites of the World Scleroderma Congress, 2014
D Furst (USA)

12:30–13:00 Closing Ceremony
Leptis Magna Room
Workshops will be held on **Thursday, February 6**.

90 minutes workshops will be repeated twice, 180 minutes workshops all at once.

Reservation is requested. Left places can be booked at the “New Registration” desk at the registration desk.

Coordinator: Phil Clements (USA)

**90 minutes workshops**
The following 90 minutes workshops will be held twice:

First time: from 13:30 to 15:00
Second time: from 15:15 to 16:45

A coffee break will be served from 15:00 to 15:15 between the first and second time of the workshops

**Skin Scoring**
Convenors: D Furst (USA), L Czirjak (H)

**How to do skin biopsy and biologic storage**
Convenors: O Distler (CH), C Beyer (D)

**HRCT fibrosis scoring**
Convenor: A Wells (UK)

**Autoantibodies**
Convenor: T Medsger (USA)
The following workshop will be held only from 15:15 to 16:45

**Clinical features and treatment of Juvenile Systemic Sclerosis**

Convenors: I Foeldari (D), F Zulian (I)

15.15 Which child with a Raynaud Phenomenon should we follow closely?
C Pain (UK)

15.35 Classification and monitoring of juvenile systemic sclerosis
F Zulian (I)

16.00 Is juvenile systemic sclerosis a different disease from the adult onset disease?
Clinical and outcome data
I Foeldvari (D)

16.30 Discussion

**180 minutes workshops**
The following 180 minutes workshops will be held from 13:30 to 16:45.

**Nailfold Capillaroscopy**
Convenor: M Cutolo (I)

13:30 Introduction of the workshop
M Cutolo (I)

13:35 Raynaud’s phenomenon: A clinical symptom revisited
A L Herrick (UK)

14:00 From Raynaud’s phenomenon up to systemic sclerosis: understanding the role of capillaroscopy
M Cutolo (I)

14:20 Selecting the most appropriate capillaroscopic device: pros and cons
A Sulli (I)

14:35 How to distinguish the pathological capillaroscopic patterns from a normal pattern
V Smith (B)

15:05–15:20 COFFEE BREAK

15:20 How to quantitatively score the qualitative capillaroscopic patterns in systemic sclerosis
A Sulli (I)

15:35 The prognostic role of capillaroscopy for digital ulcers: from the DTD index to the CAPSTUDY model and therapeutical effects
M Cutolo (I)

16:05 Introduction and presentation patients for practical session
V Ricci (I)

16:15 Practical session with patients
All tutors

**Ultrasound in scleroderma:**
Convenor: E Naredo (E)

13:30 How to detect?
I Möller (E)

13:50 How to score?
E Naredo (E)

14:10 Workshop on joints and tendons

15:00–15:15 COFFEE BREAK
Skin
15:15  B-mode and Doppler assessment
F Porta (I)

15:35  US elastography
A Iagnocco (I)

15:55  Workshop on skin

Localized scleroderma –
diagnostic and therapeutic challenges
EFESO ROOM
Convenors: R Knobler (A), T Krieg (D)

13:30  Diagnosis and Classification of localized scleroderma and related diseases
P Moinzadeh (D)

13:40  Discussion

13:50  Systemic involvement in localized scleroderma?
Discussion round (Introduction and Chair)
I Foedvari (D), F Zulian (I)

14:15  Pseudoscleroderma – diagnostic pitfalls
C Orteu (UK)

14:25  Are there overlaps between localized and systemic scleroderma?
A Jalili (A)

14:35  Discussion

14:50–15:05  COFFEE BREAK

15:05  Potential Pathomechanisms
L Mouthon (F)

15:15  Role of Borrelia, other infections and triggers.
Discussion round (Introduction and Chair)
R Müllegger (A)

15:40  UV associated and topical treatment
U Just (A), R Knobler (A)

15:50  Cyclosporine–Therapy in localized scleroderma
K Takehara (J)

16:00  Other systemic immunosuppressive therapies and novel approaches
A Kreuter (D)

16:10  Discussion

16:20  Development of guidelines.
Discussion round (Introduction and Chair)
N Hunzelmann (D)
**FIDIA SATELLITE SYMPOSIUM**

**LEPTIS MAGNA ROOM**

**Thursday, February 6**
17:00–18:00

**Management of sclerodermic digital ulcers: a novel approach**
Chairperson: V Riccieri (I)

17:00  Management of cutaneous ulcers in sclerodermic patients
       S Guiducci (I)

17:30  Hyaluronic acid as a key factor in the wound healing process of sclerodermic cutaneous ulcers
       A Passi (I)

**ACTELION SATELLITE SYMPOSIUM**

**LEPTIS MAGNA ROOM**

**Friday, February 7**
12:00–13:30

**Tackling the organ manifestations of systemic sclerosis**
Chairpersons: Y Allanore (F), C Denton (UK)

12:00  Introduction
       C Denton (UK)

12:10  The case of Steffi (Part 1) —
       Managing the early stages of SSc
       U Mueller–Ladner (D)

12:20  Focusing on early detection of SSc and addressing initial manifestations
       M Matucci–Cerinic (I)

12:40  The case of Steffi (Part 2) — The story continues
       U Mueller–Ladner (D)
12:50  How to DETECT and manage pulmonary arterial hypertension in SSc
      D Khanna (USA)

13:10  Panel discussion
      All

13:25  Closing remarks
      Y Allanore (F)
THURSDAY, FEBRUARY 6

17:00–18:00 **Round–table Networking Meeting for Leaders of Patient Groups**
All patient association leaders welcome to this informal discussion to exchange ideas.
No powerpoint presentations. Pre–registration by email is preferred. English will be the language of the meeting; no translation will be provided this day.

18:15–20:00 **Opening Ceremony of both Medical and Patient congresses**

---

FRIDAY, FEBRUARY 7

09:00–09:10 **FESCA aisbl. Welcome**
Ann Kennedy (IRL)

09:10 Why did I get scleroderma and will I be cured?
Jaap van Laar (UK)

09:30–10:30 **Breathing**
Chairs: Beata Garay–Toth (H) & Ulf Mueller–Ladner (D)

09:30 Why is breathing so difficult?
Oliver Distler (D)

09:50 The patient perspective on lung problems
Kim Fligelstone (UK)

10:05 Questions – Interactive session

10:30–11:00 **COFFEE BREAK**

11:00–11:45 **Nutrition and the Gut**
Chairs: Nadine Paciotti (CH) & Dinesh Khanna (USA)

---

*The Medical Programme of lectures is conducted separately from the Patient Programme. The Patient Programme in Keynote Room Orange will be translated simultaneously into Italian, French, and Spanish. Interactive sessions consist of presentations and discussions.*
11:00 What can I do to help digestion processes?
   Janet Pope (CAN)

11:20 Tips for people with GI problems
   Susie Hoare (UK)

11:35 Questions

11:45–12:30 Sexuality and Pregnancy
   Chairs: Despo Charalambous–Demetriou (CYP) & Gabi Riemekasten (D)

11:45 Sexuality and Pregnancy in SSc
   Angela Tincani (I)

12:05 How I had a baby
   Johanna Berglind (S) & Jessica Thonen–Velthuizen (NL)

12:25 Questions – Interactive session

11:45–12:30 Concurrent session
   ALCANTARA ROOM
   Juvenile Scleroderma
   Chair: Kim Fligelstone (UK)
   Panel: Ivan Foeldvari (D), Clare Pain (UK) & Linda Schraven (NL).
   This is an interactive session for parents and young people with scleroderma to ask questions. In English. No translation will be provided.

11:45–12:30 Concurrent session
   TREVIRI ROOM
   For Men Only
   Chair: Kent Krarup (DK)
   Panel: Richard Silver (USA), Richard Dodds (UK) & Joep Welling (NL).
   This is an interactive session for men with scleroderma to ask questions of the panel. No women. In English. No translation will be provided.

14:00–15:00 Systemic Treatments
   Chairs: Ann Kennedy (CH) & Jaap van Laar (UK)

14:00 Transplants of different kinds—are they for me?
   Alan Tyndall (CH)

14:20 A patient perspective on transplants
   Gabrielle Verzi (I)

14:30 My story, my transplant
   Jessica Thonen–Velthuizen (NL)

14:40 Questions – Interactive session with the panel

14:00–15:00 Concurrent session
   SPALATO ROOM
   Breathing Exercises
   Physiotherapist Jadranka Brozd gives an interactive workshop on how to improve breathing.

15:00–16:00 Exercise and Therapies
   Chairs: Alexandra Portales (E) & Tony Redmond (UK)

15:00 Hand and face exercises
   Paul Briffa (UK)

15:15 Dentistry in SSc
   Roberto Rozza (I)

15:30 Useful equipment and tips
   Annelise Roennow (DK)
   followed by questions to panel

12:30–14:00 LUNCH
09:00–09:15 **New EULAR–ACR classification of SSc**  
Frank van den Hoogen (NL)

09:15–10:00 **Concurrent sessions**  
**New Treatments in Scleroderma**

In English: Chris Denton (UK)  
**ORANGE ROOM**

In French, no powerpoints:  
Yannick Allanore (F)  
**ALCANTARA ROOM**

In Spanish, no powerpoints:  
Patricia Carreira (E)  
**SPALATO ROOM**

In Italian, no powerpoints:  
Marco Matucci–Cerinic (I)  
**MERIDA ROOM**

10:00–10:45 **Ulcers and the Hands**  
Chairs: Grazia Tassini (I) & László Czirják (H)

10:00 What can be done for my digital ulcers?  
Marco Matucci–Cerinic (I)

10:20 Taking care of your ulcers  
Barbara Gemmell (AUS)

10:35 Questions to the Panel

10:00–10:45 **Concurrent session**  
**Workshop in methods of facial camouflage**

10:00 Lasers & corrective make–up for telangiectasia & more  
Antoine Fauconneau (F)

10:20 Questions and Answers  
Antoine Fauconneau (F) & Marie–Sylvie Doutre (F)

10:45 Small Group Workshops continue in this room until 12.00.

10:45–11:15 **COFFEE BREAK**

11:15–12:00 **What are your Concerns?**  
**Ask the Professor**  
Chairs: Ann Kennedy (IRL) & Joep Welling (NL)  
Panel: Chris Denton (UK) & Janet Pope (CAN)  
Interactive session. Written questions in advance would be appreciated.

12:00–13:30 **Coping with Scleroderma**  
Chairs: Annelise Roennow (DK) & Els van den Ende (NL)

12:00 Carers and Family members  
Robyn Simms (USA)

12:10 Coping with the emotional aspects of SSc  
Brett Thombs (CAN)

12:25 Fatigue and how to deal with it  
Janet Poole (USA)

12:45 Questions for the panel on coping with SSc

13:00 **Closure of Medical and Patient Congresses**

14:00 **FESCA aisbl AGM**  
Treviri Room  
for official representatives of each member organisation
PS01  DECREASE OF BRACHIAL ARTERY ENDOTHELIAL-DEPENDENT FLOW-MEDIATED DILATION CHARACTERIZES VERY EARLY SYSTEMIC SCLEROSIS (VEDOSS) PATIENTS

PS02  DIAGNOSTIC STANDARDS FOR CHILDREN WITH RAYNAUD’S PHENOMENON

PS03  ANTI-ENDOTHELIAL CELL ANTIBODIES AS BIOMARKER OF SEVERE VASCULAR MANIFESTATIONS IN SYSTEMIC SCLEROSIS
C. Muñoz Vahos, C. Goldenstein-Schainberg, V.S. Viana, S. Carrasco, E.P. Leon, E. Bonfa, G. Vasquez, P.D. Sampaio-Barros

PS04  NAILFOLD VIDEOMICROCAPILLAROSCOPY AND OTHER PREDICTIVE FACTORS ASSOCIATED WITH NEW DIGITAL ULCERS IN SYSTEMIC SCLEROSIS: RESULTS FROM THE CAP STUDY

PS05  MICRORNA-34A AND MICRORNA-155 IN RAYNAUD PHENOMENON: POSSIBLE EPIGENETIC BIOMARKERS OF ENDOTHELIAL DYSFUNCTION IN SYSTEMIC SCLEROSIS
S. Alivernini, S. Bosello, G. De Luca, M. Bocci, S. Canestri, F. Foti, C. Di Mario, B. Tolusso, G. Ferraccioli

PS06  PHOSPHODIESTERASE-5 INHIBITORS FOR THE TREATMENT OF SECONDARY RAYNAUD’S PHENOMENON: SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED TRIALS

PS07  CHARACTERIZATION OF LOWER LIMB CUTANEOUS ULCERS IN SYSTEMIC SCLEROSIS: THE ANALYSIS OF 554 LESIONS

PS08  CLINICAL FEATURES AND CHARACTERISTICS OF PATIENTS WITH DIGITAL ULCERS (DU) IN SYSTEMIC SCLEROSIS (SSC) IN THE CZECH REPUBLIC: DATA FROM THE DUO REGISTRY

PS09  PREDICTORS OF DIGITAL ULCERS IN PATIENTS WITH SECONDARY RAYNAUD PHENOMENON: CORRELATION BETWEEN CLINICAL AND HEMODYNAMIC FEATURES, CAPILLAROSCOPY, ENDOTHELIUM DYSFUNCTION AND ANGIOGENESIS BIOMARKERS
I. Silva, I. Almeida, C. Vasconcelos
IONTOPHORESIS OF TREPROMSTINL AS A TREATMENT OF ISCHEMIC DIGITAL ULCERS IN SYSTEMIC SCLEROSIS: A PROOF-OF-CONCEPT STUDY

EVALUATION OF THE EFFICACY OF SILDENAFIL ON TIME TO HEALING IN PATIENTS WITH SCLERODERMA AND ISCHAEMIC DIGITAL ULCERS (SEDUCE): PATIENTS’ CHARACTERISTICS AT BASELINE

LASER SPECKLE CONTRAST ANALYSIS TECHNIQUE FOR THE FOLLOW-UP OF DIGITAL ULCERS IN SYSTEMIC SCLEROSIS PATIENTS
B. Ruaoro, A. Sulli, T. Cannavale, E. Bernero, M.A. Cimmino, B. Seriolo, M. Cutolo

PULMONARY FIBROSIS INDUCED BY BLEOMYCIN IS DRIVEN BY HIGH COLLAGEN V AND TGF<alpha> SYNTHESIS

DISTORTED LUNG FRAMEWORK IS RELATED TO IL-17+ CELLS IMMUNOEXPRESSION IN SYSTEMIC SCLEROSIS
A. Pereira Velosa, MA. Paiva, PC. Andrade, MP. Rangel, RB. Christmann, EM. Eher, SM. Fernezlian, ER. Parra, WR. Teodoro, VL. Capelozzi

DOES MYCOPHENOLATE MOFETIL (MMF) HAVE AN EFFECT ON PULMONARY HEMODYNAMICS? OBSERVATIONS FROM THE PULMONARY HYPERTENSION ASSESSMENT AND RECOGNITION OF OUTCOMES IN SCLERODERMA (PHAROS) COHORT
L. Saketkoo, M. Lammi, J. Gordon, P. Lauto, V. Steen

DEVELOPMENT OF A COMPOSITE OUTCOME MEASURE FOR SYSTEMIC SCLEROSIS-RELATED INTERSTITIAL LUNG DISEASE
E. Volkmann, N. Li, D. Tashkin, D. Furst, R. Elashoff

LUNG ULTRASOUND FOR DETECTING INTERSTITIAL LUNG DISEASE IN PATIENTS WITH SYSTEMIC SCLEROSIS
R. Lopez Martinez, R. Hassan, L. Lubertino, V. Cosentino, M. Barth, C. Saenz, M. Binda, S. Montoya, E. Kerzberg

INTERSTITIAL LUNG DISEASE IN SYSTEMIC SCLEROSIS: CLINICAL PRESENTATION AND COURSE DIFFERENCES BETWEEN PM/SCL AND SCL-70 ANTIBODIES
A. Guillen-Del Castillo, C.P. Simeon-Aznar, V. Fonollosa-Pia, S. Alonso-Vila, A. Fernandez-Codina, A. Selva-O’Callaghan, M. Vilardell-Tarres

LONG TERM FOLLOW-UP AFTER INTRAVENOUS CYCLOPHOSPHAMIDE PULSE THERAPY FOR SCLERODERMA INTERSTITIAL LUNG DISEASE: RESULTS OF A SINGLE CENTER EXPERIENCE

PULMONARY ARTERIAL HYPERTENSION (PAH) IN A CONTEMPORARY DRUG REGISTRY: RESULTS OF THE VOLT STUDY, WITH AN EMPHASIS ON PAH ASSOCIATED WITH CONNECTIVE TISSUE DISEASE (CTD)
J.L. Vachiéry, J. Langley, A.J. Peacock, O. Sitbon, N. Galié

AUTOANTIBODY PROFILE IN SYSTEMIC SCLEROSIS ASSOCIATED PULMONARY HYPERTENSION
V. Sobanski, S. Nihtyanova, B. Lynch, B. Schreiber, J. Harvey, C. Handler, C. Denton, G. Coghlan

RELEVANCE OF THE 6-MINUTE WALKING TEST IN ASSESSING THE SEVERITY OF PULMONARY ARTERIAL HYPERTENSION ASSOCIATED WITH SYSTEMIC SCLEROSIS, WITHOUT INTERSTITIAL LUNG DISEASE
S. Sangue, D. Launay, O. Sitbon, E. Hachulla, L. Mouthon, L. Guillemin, L. Rottat, P. Clerson, J.F. Cordier, G. Simonneau, M. Humbert

COST SAVINGS WITH A BIOMARKER-BASED SCREENING ALGORITHM FOR PULMONARY ARTERIAL HYPERTENSION IN SYSTEMIC SCLEROSIS
PS24  VALUE OF SYSTOLIC PULMONARY ARTERIAL PRESSURE AS A PROGNOSTIC FACTOR OF DEATH IN SYSTEMIC SCLEROSIS EUSTAR POPULATION

PS25  ABERRANT BMP SIGNALLING MAY CONTRIBUTE TO PULMONARY COMPLICATIONS IN A TGF DEPENDENT MURINE MODEL OF SCLERODERMA
A. Gilbane, E C. Derrett-Smith, A. Pearce, C.P. Denton, A M. Holmes

PS26  CHARACTERISATION OF LATE-OUTGROWTH ENDOTHELIAL PROGENITOR CELLS FROM SYSTEMIC SCLEROSIS PATIENTS

PS27  AUTOANTIBODIES TARGETING ANGIOTENSIN TYPE 1 AND ENDOTHELIN TYPE A RECEPTORS AS BIOMARKERS AND MEDIATORS OF SYSTEMIC SCLEROSIS ASSOCIATED PULMONARY ARTERIAL HYPERTENSION

PS28  SUBCLINICAL BIVENTRICULAR SYSTOLIC FUNCTION IS IMPAIRED IN PATIENTS WITH SYSTEMIC SCLEROSIS: A SPECKLE TRACKING-BASED ECHOCARDIOGRAPHIC STUDY
ST. Sahin, S. Yurdakul, N. Yilmaz, Y. Cagatay, S. Aytekin, S. Yavuz

PS29  IMPAIRED FUNCTIONAL CAPACITY IN PATIENTS WITH SYSTEMIC SCLEROSIS IS RELATED TO RIGHT VENTRICLE DYSFUNCTION

PS30  MMP12 CONTRIBUTES TO HEART AND SKIN FIBROSIS IN ANGIOTENSIN II MODEL
L. Stawski, M. Trojanowska, P. Haines

PS31  RELATIONSHIP BETWEEN INTERLEUKIN-6 AND CARDIAC INVOLVEMENT IN SYSTEMIC SCLEROSIS

PS32  EXTENSION OF CARDIAC DAMAGE THROUGH THE DELAYED ENHANCEMENT OF CARDIAC MAGNETIC RESONANCE: PREDICTIVE VALUE OF A COMBINED APPROACH BASED ON CLINICAL AND LABORATORY FINDINGS, EKG-HOLTER AND CARDIAC MR

PS33  KEY ROLE OF CARDIAC BIOMARKERS IN THE ASSESSMENT OF SYSTEMIC SCLEROSIS: CONTRIBUTION OF HIGH SENSITIVITY CARDIAC TRO Ponin
J. Avouac, C. Meune, C. Chenevier-Gobeaux, D. Borderie, A. Kahan, Y. Allanore

PS34  THE ROLE OF INFLAMMATORY PROGENITORS IN MYOCARDIAL FIBROGENESIS IN THE INFLAMMATORY DILATED CARDIOMYOPATHY

PS35  AN INTERNATIONAL COLLABORATION TO CONDUCT LARGE-SCALE TRIALS OF NON-PHARMACOLOGICAL INTERVENTIONS IN SCLERODERMA: THE SCLERODERMA PATIENT-CENTERED INTERVENTION NETWORK (SPIN)
L. Kwakkenbos, L. Jewett, B. Thoms, SPIN investigators

PS36  EARLY MORTALITY IN AUSTRALIAN AND CANADIAN SCLERODERMA PATIENTS: RATIONALE FOR ESTABLISHING A MULTI-NATIONAL INCEPTION COHORT OF PATIENTS WITH SYSTEMIC SCLEROSIS
M. Nikpour, M. Hudson, W. Stevens, C. Rabusa, S. Tatibouet, S. Proudman, M. Baron

PS37  IMPACT OF AUTOANTIBODY PROFILE ON SURVIVAL IN SYSTEMIC SCLEROSIS
S. Nihtyanova, V. Ong, C. Denton
DEVELOPING AN INTERVENTION FOR BODY IMAGE DISTRESS IN SYSTEMIC SCLEROSIS: AN UPDATE FROM THE SCLERODERMA PATIENT-CENTERED INTERVENTION NETWORK (SPIN)

IMPACT OF MALE SEX ON SURVIVAL IN SYSTEMIC SCLEROSIS
H. Hussein, C. Chau, S.R. Johnson

APPEARANCE DISSATISFACTION, SOCIAL DISCOMFORT, AND HELPLESSNESS IN PATIENTS WITH SYSTEMIC SCLEROSIS
S. Gholizadeh, S. Mills, R. Fox, P. Clements, S. Kafaja, V. Malcarne, D. Khanna, D. Furst

PREDICTION OF WORSEN ING OF SKIN FIBROSIS IN PATIENTS WITH DIFFUSE SYSTEMIC SCLEROSIS USING THE EULAR SCLERODERMA TRIALS AND RESEARCH (EUSTAR) REGISTRY AND VALIDATION IN A SECOND COHORT
B. Maurer, N. Graf, B.A. Michel, C. Metzig, V. Lanius, D. Khanna, O. Distler

MRI INFLAMMATORY LESIONS OF THE HAND COULD BE PREDICTORS OF DIGITAL ULCERS, DISEASE ACTIVITY AND LOWER FUNCTIONAL CAPACITY IN SYSTEMIC SCLEROSIS
B. Stamenkovic, A. Stankovic, J. Nedovic, S. Stojanovic, V. Zivkovic, A. Dimic, N. Damjanov

EVALUATION OF BLOOD PERFUSION IN DIFFERENT SKIN AREAS OF SYSTEMIC SCLEROSIS PATIENTS BY LASER SPECKLE CONTRAST ANALYSIS AND CORRELATIONS WITH NAILFOLD MICROANGIOPATHY EXTENT
A. Sulli, B. Ruaro, F. Ravera, D. Stanciu, C. Pizzorni, M. Cutolo

CORRELATION BETWEEN BLOOD PERFUSION AND DERMAL THICKNESS IN DIFFERENT SKIN AREAS OF SYSTEMIC SCLEROSIS PATIENTS
B. Ruaro, A. Sulli, E. Alessandri, G. Ferrari, M.A. Cimmino, M. Cutolo

STABILISATION OF MICROCIRCULATION IN EARLY SYSTEMIC SCLEROSIS PATIENTS WITH DIFFUSE SKIN INVOLVEMENT FOLLOWING RITUXIMAB TREATMENT
V. Smith, C. Pizzorni, V. Riccieri, S. Decuman, Y. Piette, A. Sulli, E. Deschepper, F. De Keyser, M. Cutolo

ASSESSMENT OF SKIN BLOOD FLOW AND STRUCTURE IN LOCALISED SCLERODERMA USING NON-INVASIVE IMAGING

VIRTUAL TOUCH IMAGING AND QUANTIFICATION™: IS IT POSSIBLE TO DISTINGUISH “UNAFFECTED” SKIN IN SCLERODERMA PATIENTS FROM HEALTHY SKIN?

IMAGING OF SCLERODERMA WITH OPTICAL COHERENCE TOMOGRAPHY
HC. Ring, A. Hussain, M. Mogensen

TOWARDS PERSONALIZED MEDICINE: MOLECULAR DIAGNOSTICS FOR SYSTEMIC SCLEROSIS - UTILIZING GENE EXPRESSION PROFILING TO GUIDE PATIENT MANAGEMENT
Y. Nesbeth, T. Wood, M. Hinchcliff, S. Podlusky, J. Reder, M. Whitfield

ANTI IL-6 RECEPTOR ANTAGONIST FOR THE TREATMENT OF DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS
R. Baytnner-Zamir, Y. Levy

SAFETY AND EFFICACY OF COMBINED B CELL-DEPLETION THERAPY WITH RITUXIMAB AND CYCLOPHOSHAMIDE IN SYSTEMIC SCLEROSIS
L. Picco, G. De Marchi, E. Di Poi, P. Masolini, S. De Vita

5-YEAR FOLLOW UP OF ABATACEPT THERAPY FOR SYSTEMIC SCLEROSIS WITH CHRONIC ARTHRITIS
E. Di Poi, P. Masolini, G. De Marchi, L. Picco, S. De Vita

WHAT ARE SYSTEMIC SCLEROSIS-RELATED CALCINOSES MADE OF AND CAN WE DISSOLVE THEM?
C. Lydon, T. Lowe, P. Withers, A. Herrick, P. O’Brien, R. Winpenny
PS54  ANTICENTROMERE ANTIBODY, DISEASE DURATION AND HISTORY OF SURGICAL DEBRIDEMENTS PREDICT CALCINOSIS IN PATIENTS WITH SYSTEMIC SCLEROSIS  
M. Mahmood, J. Wilkinson, J. Manning, A. Herrick

PS55  ANTI-CARBAMYLATED PROTEIN ANTIBODIES ARE PRESENT IN SYSTEMIC SCLEROSIS  
V. Riccieri, I. Bartosiewicz, M. Pendolino, K. Stefanantoni, N. Iannace, C. Alessandri, G. Valesini

PS56  THE DEVELOPMENT OF A MODIFIED HAND MOBILITY IN SCLERODERMA TEST AND ITS POTENTIAL AS AN OUTCOME MEASURE IN SYSTEMIC SCLEROSIS  
G. Sandqvist, J.Å. Nilsson, D.M. Wuttge, R. Hesselstrand

PS57  ANALYSIS OF PATIENTS WITH SYSTEMIC SCLEROSIS AND RHEUMATOID ARTHRITIS OVERLAP SYNDROME.  
A. Parma, A. Della Rossa, A. D’Ascanio, S. Barsotti, C. Stagnaro, S. Bombardieri

PS58  ANTI-CCP ANTIBODIES AND RHEUMATOID FACTOR IN SYSTEMIC SCLEROSIS – PREVALENCE AND USEFULNESS.  
E. Wielosz, M. Dryglewksa, M. Majdan

PS59  EFFECTS OF PRESSURE RELIEVING INSOLES FOR FOOT PROBLEMS IN PEOPLE WITH SSC: THE PISCES RANDOMIZED CONTROLLED TRIAL  

PS60  HAND DISABILITY IN PATIENTS WITH SYSTEMIC SCLEROSIS: THE ROLE OF AN INDIVIDUALIZED REHABILITATION PROGRAM  
A. Volpe, G. Apolloni, G. Barausse, R. Bortolotti, F. Cavatorta, S. Peccatori, M. Felicetti, C. Ferri, G. Paolazzi

PS61  SYSTEMIC SCLEROSIS-RELATED SYNOVITIS: IMAGING FEATURES AND HISTOLOGICAL EXAMINATION OF THE SYNOVIAL TISSUE  
M. Stoenoiu, C. Galant, M. Vanthuyne, O. Barbier, O. Cornu, BR. Lauwerys, A. Nzeusseu-Toukap, F.E. Lecouvet, F. A. Houssiau

PS62  EVALUATION OF THE PATIENT-REPORTED OUTCOMES MEASUREMENT INFORMATION SYSTEM (PROMIS®) GASTROINTESTINAL (GI) SYMPTOMS MEASURES IN SYSTEMIC SCLEROSIS (SSC)  
D. Khanna, L. Chang, G. Melmed, R. Hays, P. Khanna, B. Spiegel

PS63  UPPER GASTROINTESTINAL BLEEDING PREDICTS HIGHER MORTALITY IN SYSTEMIC SCLEROSIS PATIENTS  

PS64  NUTRITIONAL SUPPORT IN PATIENTS WITH SYSTEMIC SCLEROSIS  
V. Ortiz-Santamaria, A. Recasens, C. Puig, C. Soldevila, J. Cuquet

PS65  VASCULAR EVENTS ARE RISK FACTORS FOR ANAL INCONTINENCE IN SYSTEMIC SCLEROSIS: A STUDY ON MORPHOLOGY AND FUNCTIONAL PROPERTIES AS MEASURED BY ANAL ENDOSONOGRAPHY AND MANOMETRY  
R. Hesselstrand, K. Andréasson, M. Starck, A. Scheja, I. Bartosik

PS66  FAECAL LEVELS OF CALPROTECTIN IN SYSTEMIC SCLEROSIS ARE STABLE OVER TIME AND ARE HIGHER COMPARED TO PRIMARY SJÖGREN’S SYNDROME AND RHEUMATOID ARTHRITIS  
K. Andréasson, T. Saxne, A. Scheja, I. Bartosik, T. Mandl, R. Hesselstrand

PS67  GASTROINTESTINAL MUCOSAL ABNORMALITIES USING VIDEOCAPSULE ENDOSCOPY IN SYSTEMIC SCLEROSIS  
I. Marie, M. Antonietti, E. Hachulla, B. Bienvenu, A. Smail, P. Duhaute, S. Dominique, PY. Hatron, E. Houivet, H. Levesque, J. Benichou, P. Ducrotte

PS68  ASSESSMENT OF VALIDITY OF GASTROINTESTINAL MORPHOLOGY PROCEDURES AND BACTERIAL OVERGROWTH TESTS USED IN SYSTEMIC SCLEROSIS, BASED ON OMERACT CRITERIA  
Y. Braun-Moscovici, M. Braun, D. Khanna, A. Balbir-Gurman, D.E. Furst
<table>
<thead>
<tr>
<th>Poster Number</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>PS69</td>
<td>SEXUAL DYSFUNCTION: THE PHYSICAL AND PSYCHOLOGICAL BURDEN ON WOMEN IN SYSTEMIC SCLEROSIS</td>
<td>T. Ngcozana, C. Denton, V. Ong</td>
</tr>
<tr>
<td>PS70</td>
<td>IN WOMEN WITH SYSTEMIC SCLEROSIS, SEXUAL FUNCTION IS AFFECTED BY DISEASE-RELATED AND PSYCHOLOGICAL CONCERNS</td>
<td>A. Del Rosso, S. Maddali Bongi, S. Mikhaylova, M. Baccini, M. Matucci Cerinic</td>
</tr>
<tr>
<td>PS71</td>
<td>SEXUAL DYSFUNCTION IS ASSOCIATED WITH ANXIETY AND HIGHER BODY MASS INDEX IN WOMEN WITH SYSTEMIC SCLEROSIS</td>
<td>M. Coutinho, I. Ruela, T. Santiago, C. Duarte, J.A.P. da Silva, M.J. Salvador</td>
</tr>
<tr>
<td>PS72</td>
<td>THE VASCULAR HYPOTHESIS OF FEMALE AND MALE SEXUAL DYSFUNCTION</td>
<td>E. Rosato, S. Quarta, L. Trombetta, S. Pisarri, F. Salsano</td>
</tr>
<tr>
<td>PS75</td>
<td>AUTOLOGOUS FAT TRANSFER FOR DIGITAL ULCERS TREATMENT IN SYSTEMIC SCLEROSIS</td>
<td>G. Erba, E. Allevi, I. Mazzola, M. Del Bene, M.R. Pozzi</td>
</tr>
<tr>
<td>PS76</td>
<td>LUNG TRANSPLANTATION IN SISTEMIC SCLEROSIS: EXPERIENCE IN A SPANISH CENTER</td>
<td>A. Fernández-Codina, C. Simeón, C. Berastegui, G. Silveira, A. Guillen, V. Fonollosa, V. Monforte, M. Vilarde-Tarrés, A. Román</td>
</tr>
<tr>
<td>PS80</td>
<td>NO CORRELATION OF CD4+ LYMPHOPENIA AND CLINICAL RESPONSE TO AUTOLOGOUS STEM CELL TRANSPLANTATION FOR SYSTEMIC SCLEROSIS</td>
<td>M. Wagner, I. Kötter, W. Vogel, L. Kanz, J. Henes</td>
</tr>
<tr>
<td>PS82</td>
<td>HUMAN ADIPOSE-DERIVED STROMAL CELLS FOR CELL-BASED THERAPIES IN THE TREATMENT OF COUTANEOUS MANIFESTATIONS IN PATIENTS AFFECTED BY SYSTEMIC SCLEROSIS (SSC)</td>
<td>N. Scuderi, P. Fino, M.G. Onesti</td>
</tr>
<tr>
<td>PS83</td>
<td>ANGIOTENSIN RECEPTOR TYPE 1 AND ENDOTHELIN RECEPTOR TYPE A ON IMMUNE CELLS MEDIATE MIGRATION AND THE EXPRESSION OF IL-8 AND CCL18 WHEN STIMULATED BY AUTOANTIBODIES FROM SYSTEMIC SCLEROSIS PATIENTS</td>
<td>J. Günther, A. Kill, MO. Becker, E. Siegert, M. Radic, G. Riemekasten</td>
</tr>
</tbody>
</table>
PS84  ANTI-AT1R AND ANTI-ETAR AUTO ANTIBODIES FROM PATIENTS WITH SSC AND THEIR AGONISTIC EFFECTS

PS85  SYSTEMIC SCLEROSIS SERA AFFECT ANGIogenesis, WOUND HEALING CAPACITY AND MIGRATION OF DERMAL BLOOD MICROVASCULAR ENDOTHELIAL CELLS: THERAPEUTIC IMPLICATIONS OF CYCLOPHOSPHAMIDE
A. Borghini, M. Manetti, F. Nacci, E. Romano, A.F. Milia, S. Guiducci, M. Matucci-Cerinic, L. Ibba-Manneschi, E. Weber

PS86  FROM MICROVASCULATURE TO FIBROBLAST: CONTRIBUTION OF ANTI-ENDOTHELIAL CELL ANTIBODIES (AECA) IN SYSTEMIC SCLEROSIS
C. Corallo, B. Franci, A. Montella, F. D’Onofrio, R. Nuti, N. Giordano

PS87  CIRCULATING ANGIogenic FACTORS IN SSC PATIENTS – ASSOCIATION WITH CLINICAL MANIFESTATIONS
M. Madej, A. Luczak, B. Nowak, E. Morgiel, L. Korman, P. Wiland

PS88  CIRCULATING ENDOTHELIAL MICROPARTICLES REFLECT MICROVASCULAR IMPAIRMENT IN PATIENTS WITH SYSTEMIC SCLEROSIS
O. Kowal-Bielecka, M. Bielecki, M. Michalska-Jakubus, D. Krasowska

PS89  IGG SUBCLASSES OF AUTO ANTIBODIES DIRECTED AGAINST THE ANGIOTENSIN RECEPTOR TYPE 1 AND THE ENDOTHELIN RECEPTOR TYPE A AND THEIR CLINICAL RELEVANCE
J. Günther, A. Kill, M.O. Becker, E. Siegert, H. Heidecke, G. Riemekasten

PS90  DECREASED EXPRESSION OF NEUROPILIN-1 IN SYSTEMIC SCLEROSIS: POTENTIAL CONTRIBUTION TO IMPAIRED ANGIogenesis
E. Romano, M. Manetti, C. Mazzotta, I. J. Da Silva Chora, S. Bellando-Randone, J. Blagojevic, L. Ibba-Manneschi, M. Matucci-Cerinic, S. Guiducci

PS91  INVOLVEMENT OF PLEXIND1/SEMAPHORIN 3E PATHWAY ON THE DYSREGULATION OF VASCULAR TONE CONTROL IN SSC PATIENTS
C. Mazzotta, E. Romano, C. Bruni, M. Manetti, G. Lepri, S. Bellando-Randone, J. Blagojevic, I. J. Da Silva Chora, A. Radicati, M. Matucci-Cerinic, S. Guiducci

PS92  DECREASED EXPRESSION OF THE ENDOTHELIAL CELL-DERIVED FACTOR EGFL7 CONTRIBUTES TO IMPAIRED ANGIogenesis AND VASCULOgenesis IN SYSTEMIC SCLEROSIS

PS93  NAILFOLD CAPILLAROSCOPIC ASSESSMENT AND VASCULAR BIOMARKERS IN SYSTEMIC SCLEROSIS: LOW CD40L LEVELS IN PATIENTS WITH LATE SCLERODERMA PATTERNS
Y. Yalcinkaya, S. Cinar, S. Kamali, O. Pehlivan, N. Alpay, L. Ocal, G. Deniz, M. Inanc

PS94  DIAGnostic TARGETS REVEALED BY HIGH-RESOLUTION PROTEIN PROFILING OF HUMAN PLASMA MICROPARTICLES
L. Iversen, O. Østergaard, S. Jacobsen, N. Heegaard

PS95  S100A4 SERUM LEVELS CORRELATE WITH SKIN FIBROSIS, LUNG INVOLVEMENT AND DISEASE ACTIVITY IN SYSTEMIC SCLEROSIS

PS96  SECRETED FRIZZLED-RELATED PROTEIN 4 CAN BE INDUCED BY TRANSFORMING GROWTH FACTOR-BETA, IS REGULATED BY CAVEolin-1 AND CAN INDUCE NON-CANONICAL WNT SIGNALING IN FIBROBLASTS
J. Gillespie, A. Giuseppina, P. Emery, M.F. McDermott, F. Del Galdo

PS97  TARGETING IL-6 BY BOTH PASSIVE OR ACTIVE IMMUNIZATION STRATEGIES PREVENTS INFLAMMATION-DRIVEN SKIN FIBROSIS
J. Avouac, L. Desallais, M. Fiéchet, M. Elhai, J.F. Zagury, Y. Allanore
PS98 ENDOTHELIN-1 MEDIATES DOWNSTREAM PROFIBROTIC EFFECTS BY TRANSFORMING GROWTH FACTOR-BETA 1 IN SYSTEMIC SCLEROSIS SKIN FIBROBLASTS
T. Higuchi, Y. Kawaguchi, K. Takagi, Y. Ota, Y. Katsumata, T. Gono, H. Yamanaka

PS99 THE ROLE OF MCSF AND ENDOTHELIN 1 IN FIBROCYTE DIFFERENTIATION
S. Trinder, X. Shi-wen, B. Ahmed-Abdi, R. Good, A. Gilbane, C. Denton, D. Budd, D. Abraham, A. Holmes

PS100 SIMVASTATIN MODULATES AORTIC INTIMA/MEDIA THICKNESS IN AN ANIMAL MODEL OF SYSTEMIC SCLEROSIS

PS101 SUSCEPTIBILITY OR RESISTANCE TO EXPERIMENTAL LUNG FIBROSIS IS PREDICTED BY RESIDENT LUNG FIBROBLAST GENE EXPRESSION SIGNATURE
E. Derrett-Smith, R. Hoyles, K. Khan, D. Abraham, C. Denton

PS102 EXCESSIVE FIBROSIS AND PULMONARY VASCULAR REMODELING IN FRA-1 TRANSGENIC MICE
H. Yasuoka, Y. Okazaki, A. Tam, Y. Tamura, I. Takada, K. Matsuo, T. Takeuchi, M. Kuwana

PS103 INCREASED FREQUENCY OF INTERLEUKIN-2 PRODUCTION BY TH17 LYMPHOCYTES IN PERIPHERAL BLOOD OF SYSTEMIC SCLEROSIS PATIENTS
M.G. Santiago, M. Raposo, C. Duarte, M.J. Salvador, A. Paiva, J.A.P. Da Silva

PS104 ROLE OF IL-13-PRODUCING CD8+ T CELLS IN THE PATHOGENESIS OF SYSTEMIC SCLEROSIS

PS105 TOLL LIKE RECEPTOR 3: A CROSSROAD IN SCLERODERMA ETIOPATHOGENESIS
C.B. Chighizola, E. Raschi, L. Cesana, S.C. Uceda Renteria, M. Biggioggero, M.O. Borghi, P.L. Meroni

PS106 ENHANCED IL-8 PRODUCTION BY MONOCYTES IN SYSTEMIC SCLEROSIS PATIENTS WITH PULMONARY FIBROSIS
M.G. Santiago, S. Horta, M.J. Salvador, A. Paiva, J.A.P. Da Silva

PS107 MOLECULAR ASPECTS OF IL-13 UP-REGULATION BY CD8+ T CELLS FROM SSC PATIENTS
S. Cascio, A. Moss, M. Jessup, D. B. Stolz, C. Milcarek, T. A. Medsger, P. Fuschiotti

PS108 EXPRESSION OF THE TRANSCRIPTION FACTOR FORKHEAD BOX E3 (FOXE3) IN PERIPHERAL BLOOD MONONUCLEAR CELLS OF PATIENTS WITH SYSTEMIC SCLEROSIS
E. Favoino, I. E. Favia, L. Digiglio, F. Perosa

PS109 ANTIBODIES ANTI-RO/SSA IN SYSTEMIC SCLEROSIS

PS110 MEMORY (CD27+) B CELL IMPAIRMENT IS A CHARACTERISTIC FEATURE OF PATIENTS WITH SYSTEMIC SCLEROSIS AND PULMONARY FIBROSIS

PS111 IRF8 GENE CONTRIBUTES TO DISEASE SUSCEPTIBILITY AND INTERACTS WITH NF-KB BY MODULATING INTERFERON SIGNATURE IN PATIENTS WITH SYSTEMIC SCLEROSIS

PS112 ACTIVATION OF LIVER X RECEPTORS INHIBITS EXPERIMENTAL FIBROSIS BY INTERFERING WITH INTERLEUKIN-6 RELEASE FROM MACROPHAGES

PS113 CORRELATION BETWEEN SHORTER DISEASE DURATION IN SYSTEMIC SCLEROSIS (SSC) AND ANTI-COLLAGEN TYPE V
M. Ugolini, E. Mantovani, V. Dinis, V. Bonoldi, A. Ribeiro, N. Yoshinari, D. Andrade
SYSTEMIC SCLEROSIS AND OCCUPATIONAL EXPOSURE: A CASE CONTROL STUDY OF 100 PATIENTS AND 300 CONTROLS

A GENOME-WIDE ASSOCIATION STUDY FOLLOW-UP SUGGESTS A POSSIBLE ROLE FOR PPARG IN SYSTEMIC SCLEROSIS SUSCEPTIBILITY

PREVALENCE OF ANTI-RNA POLYMERASE III ANTIBODIES IN SYSTEMIC SCLEROSIS: NEW DATA FROM A FRENCH COHORT, SYSTEMATIC REVIEW AND META-ANALYSIS

SEMAPHORIN 3A AS A POSSIBLE IMMUNOREGULATOR IN SYSTEMIC SCLEROSIS

INFLUENCE OF ALPHA 2 DO COLLAGEN V OVEREXPRESSION IN PHYSIOPHATOLOGY OF FIBROSIS SYSTEMIC SCLEROSIS PATIENTS
J. Morais, P. Martin, APP. Velosa, PC. Andrade, IB. Cruz, EC. Miracca, FAC. Barrence FAC, S. Carrasco, C. Goldeinstein-Schainberg, MA. Nagai, ER. Parra, VL. Capelozi, WR. Teodoro

SERUM FREE LIGHT CHAINS OF IMMUNOGLOBULINS ARE ASSOCIATED WITH DISEASE ACTIVITY IN SYSTEMIC SCLEROSIS: A PROSPECTIVE AND CONTROLLED STUDY

COLLAGEN CROSS LINKING ENZYMES LOXL2 AND PLOD2 SHOW NO ASSOCIATION WITH SYSTEMIC SCLEROSIS
S. Guerra, S. Ziaj, B. Ahmed Abdi, K. Khan, I. Papaioannou, C. Denton, D. Abraham, C. Fonseca

VITAMIN D ANTIBODIES IN SYSTEMIC SCLEROSIS PATIENTS: ANTIBODIES PRESENCE AND CLINICAL AND LABORATORY CORRELATIONS
N.N. Carmel, A. Lavrov, P. Rotman, Y. Levy

A LOSS OF TELOCYTES CHARACTERIZES FIBROSIS OF MULTIPLE ORGANS IN SYSTEMIC SCLEROSIS
M. Manetti, I. Rosa, L. Messerini, M. Matucci-Cerinic, L. Ibba-Manneschi

INCREASED FREQUENCY OF TH1 AND TC1 LYMPHOCYTES PRODUCING TUMOR NECROSIS FACTOR ALPHA IN PERIPHERAL BLOOD OF LATE-STAGE SYSTEMIC SCLEROSIS
M.G. Santiago, M. Raposo, C. Duarte, M.J. Salvador, A. Paiva, J.A.P. Da Silva

HELICOBACTER PYLORI AS A TRIGGER OF SYSTEMIC SCLEROSIS: IMMUNOLOGICAL ASPECTS
C. Liaskos, A. Varna, T. Simopoulou, A. Mavropoulos, M. Mytilinaiou, EL. Rigopoulou, DP. Bogdanos, LI. Sakkas

ROLE OF ANGIOSTATIN AND ENDOSTATIN IS SYSTEMIC SCLEROSIS
I. Almeida, A. Gomes, A. Puga, I. Silva, M. Lima, C. Vasconcelos

ROLE OF CD8+ LYMPHOCYTES IN SYSTEMIC SCLEROSIS
I. Almeida, S. Vieira Silva, M. Santos, M. Lima, C. Vasconcelos

PROPYLTHIOURACIL ATTENUATES AORTIC VASCULOPATHY IN AN ANIMAL MODEL OF SYSTEMIC SCLEROSIS

THE RELATIONSHIP BETWEEN NAILFOLD CAPILLAROSCOPIC ASSESSMENT AND TELANGIECTASIA SCORE WITH SEVERITY OF PERIPHERAL VASCULAR INVOLVEMENT IN SYSTEMIC SCLEROSIS
PS129  Efficacy of Bosentan in the Treatment of Raynaud’s Phenomenon: Analysis of Three Cohorts of Patients
S. Parisi, M. Scarati, M. Priora, M. Galeazzi, F. Bellisai, S. Manganelli, L. Emmi, E. Beccastrini, A. Ianniello, E. Fusaro

PS130  Correlations Between Peripheral Microvascular Disease Severity and Vitamin D Serum Levels in Systemic Sclerosis Patients
A. Sulli, S. Paolino, V. Smith, G. Botticella, C. Pizzorni, A. Casabella, B. Seriolo, M. Cutolo

PS131  Scleroderma Digital Ulcer Healing: Beneficial Role of Bosentan and Opponent Role of Skin Digital Fibrosis
M. Inglese, F. Molinaro, M. Bernal, M. Sperandeo, G. Mazzonecoli, V. D’Alessandro, S. Stisi, A. De Cata

PS132  Development of a Mouse Model of Scleroderma-Related Skin Ulcer
S. Kotzki, J.L. Cracowski, O. Combes, C. Arnaud, D. Godin-Ribuot, M. Roustit

PS133  Correlations Between Virtual Touch Imaging and Quantification Absolute Skin Stiffness, Nailfold Capillaroscopy Pattern and Digital Ulcers in Systemic Sclerosis Patients

PS134  Ginkgo Biloba Reduces the Duration and Severity of Raynaud’s Attacks of Patients with Systemic Sclerosis
Z. Mirfeizi, MH. Jokar, M. Mirfeizi

J. Meijs, A. Voskuyl, J. Bloemsaat-Minekus, M. Vonk

PS136  Acupressure for the Treatment of Raynaud’s Phenomenon: A PILOT Randomized Controlled Trial
H. Gladue, V. Berrocal, R. Harris, P. Tsou, D. Khanna

PS137  Comparison of Postocclusive Hyperemia in Systemic Sclerosis and Primary Raynaud’s Phenomenon

PS138  Nailfold Videocapillaroscopy and Serum VEGF as Biomarkers of Severity in Systemic Sclerosis?
M. De Santis, F. Cavaciocchi, C. Crotti, A. Ceribelli, A. Laria, B. Marasini, M.S. Massarotti, C. Selmi

PS139  Scleroderma and Digitals Ulcers Treatment Access
C. Bento, N. Cavilla, S. Di Stefano

PS140  Digital Ulcers in Systemic Sclerosis

PS141  Epidemiological Study for the Early Detection of Systemic Sclerosis in Patients with Raynaud Phenomenon
E. Beltián-Catalán, JA. Román-Ivorra, C. Feced, J. Alegre

PS142  Evolution of Patients with Scleroderma and Severe Distal Ischemic Events After Stopping Treatment with Bosentan

PS143  Bosentan Treatment of Digital Ulcers Related to Systemic Sclerosis
S. Giancotti, R. Cimino, C. Pintaudi, S. Mazzuca

PS144  Functional Vascular Abnormalities in Systemic Sclerosis (SSC) Might be Useful for Disease Sub Setting: A Laser Speckle Contrast Study
A. Della Rossa, A. d’Ascanio, C. Stagnaro, S. Barsotti, M. Cazzato, M. Mosca, S. Bombardieri

PS145  Nailfold Capillaroscopy by Digital USB-Microscope: An Inexpensive and Easy Method for Identifying Scleroderma Pattern
H. Bitter, G. Myklebust
PS146  MICROSCIRCULATORY EFFECTS OF ILOPROST ON NEW DIGITAL ULCERS IN PATIENTS WITH SYSTEMIC SCLEROSIS
C. Pintaudi, R. Cimino, S. Giancotti, S. Mazzuca

PS147  SURGICAL TREATMENT OF SCLERODERMA – RE-THINKING THE ROLE AND TIMING OF PERIPHERAL SYMPATHECTOMY IN THE HAND
J. Chang, A. Momeni, S. Sorice, L. Chung

PS148  INTRAVENOUS ILOPROST TREATMENT SIDE EFFECT PROFILE IN PATIENTS WITH DIGITAL ULCERS DUE TO SYSTEMIC SCLEROSIS
S. Ugurlu, D. Cevirgen, B. Yalcin

PS149  DEVELOPMENT OF A NEW SCORING SYSTEM TO ASSESS DIGITAL ULCERS IN PATIENTS SUFFERING FROM SYSTEMIC SCLEROSIS

PS150  QUANTITATIVE ANALYSIS OF NAILFOLD CAPILLARY MORPHOLOGY AND CORRELATION WITH RAYNAUD’S PHENOMENON IN PATIENTS WITH FIBROMYALGIA
H. Kim, SK. Kim

PS151  OBSERVATION PATIENTS WITH RAYNAUD SYNDROM IN SLOVAK POPULATION INCLUDE CAPILLAROSCOPY FINDINGS, USING CAPILLAROSCOPY FOR SEARCHING PATIENT WITH EARLY STAGE OF SCLERODERMA
J. Lukac, O. Lukacova, J. Rovensky

PS152  COMPUTERIZED NAIL-FOLD VIDEO CAPILLAROSCOPY AND SYSTEMIC SCLEROSIS
D. Hakem, N. Ouadahi, A. Berrah

PS153  TREATMENT OF DIGITAL ULCERS IN SYSTEMIC SCLEROSIS: REVIEW OF ELEVEN PATIENTS FROM A SINGLE CENTER AND DISCUSSION ON OUTCOME
J. Matos-Costa, R. Almeida, A. A.-Oliveira, P. Pego, Y. Abuowda, I. A.-Câmara, C. Santos, Nedai

PS154  EFFECT OF SARPOGRELATE FOR RAYNAUD’S PHENOMENON SECONDARY TO SYSTEMIC SCLEROSIS
T. Makino, M. Jinnin, I. Kajihara, K. Makino, H. Ihn

PS155  CURRENT APPROACH TO DIGITAL ULCERS IN SYSTEMIC SCLEROSIS
S. Lambova, A. Batalov, H. Dobrev, L. Sapundzhiev, U. Müller-Ladner

PS156  BOSENTAN FOR DIGITAL ULCERS IN PATIENTS WITH SYSTEMIC SCLEROSIS: SINGLE-CENTER EXPERIENCE
O. Kucuksahtin, A. Ates, U. Ilgın, B. Ozturk, G. Kinikli, M. Turgay, N. Duzgun

PS157  MINIMAL CLINICALLY IMPORTANT INVESTIGATIONS IN SYSTEMIC SCLEROSIS
J. Meijs, J. De Vries, N. Ajmone, M. Ninaber, T. Huizinga, A. Schouffoer

PS158  COMBINED PULMONARY FIBROSIS AND EMPHYSEMA (CPFE) IN SYSTEMIC SCLEROSIS
N. Champiaux, V. Cottin, E. Hachulla, D. Valeyre, H. Nunes, D. Launay, B. Crestani, L. Guillemin, JF. Cordier, L. Mouthon

PS159  DYNAMICS OF DISEASE SEVERITY INDEX AND ESCSG ACTIVITY INDEX IN SSC-ASSOCIATED ILD DURING LONG-TERM FOLLOW UP
O. Ovsyannikova, O. Koneva, V. Lesnyak, L. Ananieva

PS160  THE PREVALENCE AND CLINICAL RELEVANCE OF INTERSTITIAL LUNG DISEASE ON THE HIGH-RESOLUTION COMPUTED TOMOGRAPHY (HRCT) IN EARLY SYSTEMIC SCLEROSIS PATIENTS
S. Wangkaew, J. Euathrongchit, N. Kasitanon, S. Puntana, W. Louthrenoo

PS161  PROGNOSTIC FACTORS OF FUNCTIONNAL OUTCOME IN SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE

PS162  INTERSTITIAL LUNG DISEASE IN SOUTH AFRICANS WITH SYSTEMIC SCLEROSIS
P. Ashmore, M. Tikly, M. Wong, C. Ickinger

PS163  COMPARISON OF INTERSTITIAL LUNG DISEASE CT INDEXES AND PULMONARY FUNCTION VALUES IN SISTEMIC SCLEROSIS PATIENTS
PS164  SYSTEMIC SCLEROSIS INTERSTITIAL LUNG DISEASE EVALUATION: COMPARISON BETWEEN SEMIQUANTITATIVE AND QUANTITATIVE CT ASSESSMENTS
A. Ariani, F. Lumetti, D. Santilli, F. Mozzani, M. Silva, G. Delsante, N. Sverzellati

PS165  ENHANCED ACTIVATION OF TGFBETA-RELATED SIGNALING MOLECULES IN MONOCYTES FROM HEALTHY AFRICAN AMERICANS AND SSC ILD PATIENTS
E. Tourkina, C. Reese, B. Perry, J. Heywood, M. Bonner, R.P. Visconti, R.M. Silver, S. Hoffman

PS166  CLINICAL CHARACTERISTICS OF SYSTEMIC SCLEROSIS PATIENTS WITH INTERSTITIAL LUNG DISEASE WHO DO NOT REQUIRE IMMunosuppressive TREATMENT
E. Lee, H. Kwon, E. Kang, E. Lee, Y. Song

PS167  ELEVATED SERUM LEVELS OF TUMOR-ASSOCIATED ANTIGENS IN SYSTEMIC SCLEROSIS: CORRELATION WITH LUNG FIBROSIS

PS168  RESIDUAL VOLUME: A CANDIDATE AS EARLY MARKER OF INTERSTITIAL LUNG DISEASE IN SYSTEMIC SCLEROSIS PATIENTS?
C. Rotondo, E. Praino, E. Lanciano, M. Fornaro, G. Lopalco, M. G. Nivuori, F. Iannone, G. Lapadula

PS169  A NEW METHOD TO EVALUATE THE EXTENT OF PULMONARY FIBROSIS IN PATIENTS WITH SYSTEMIC SCLEROSIS.
E. Roubi, S. Nyrén, L. Björnådal, E. Svennungsson, A. Nordin

PS170  POSSIBLE ASSOCIATION OF AMBRISENTAN WITH DETERIORATION OF CONNECTIVE TISSUE DISEASES-ASSOCIATED INTERSTITIAL LUNG DISEASE
Y. Yamasaki, H. Yamada, K. Tsuchida, H. Ogawa, S. Ozaki

PS171  LL-37: IS IT A NEW MARKER FOR INTERSTITIAL LUNG DISEASE (ILD) IN SYSTEMIC SCLEROSIS (SSC)?
M. Hizal, C. Bruni, E. Romano, C. Mazzotta, S. Guiducci, A. Tufani, M. Matucci-Cerinic

PS172  COMPARISON OF BAL AND SERUM CYTOKINES AND PREDICTIVE VALUE OF SERUM CYTOKINES IN SYSTEMIC SCLEROSIS PATIENTS

PS173  B LYMPHOCYTE DEPLETION IN SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE AFTER TREATMENT WITH STANDARD AND LOW DOSES OF RITUXIMAB

PS174  SMALL ANIMAL MRI FOR NON-INVASIVE LONGITUDINAL FOLLOW UP OF PULMONARY FIBROSIS IN MICE
E. De Langhe, G. Vande Velde, T. Dresselaers, J. Poelmans, R. Lories, U. Himmelreich

PS175  PULMONARY INVOLVEMENT IN SSC PATIENTS – A SINGLE CENTRE EXPERIENCE
I. Dobrota, A. Petcu, S. Rednic

PS176  USE OF IMMUNOSUPPRESSANTS IN SSC PATIENTS WITH INTERSTITIAL LUNG DISEASE – RESULTS OF THE DESSCIPHER PROJECT OF THE EUSTAR GROUP

PS177  ALPHA2 (V) CHAIN AND COLVA2 INDUCES THE FIBRILLOGENESIS PROCESS IN DISTORTED LUNG FRAMEWORK OF SYSTEMIC SCLEROSIS

PS178  EFFICACY AND SAFETY OF INTRAVENOUS CYCLOPHOSPHAMIDE IN SCLERODERMA LUNG DISEASE OF ELDERLY
T. Nunokawa, N. Yokogawa, K. Shimada, S. Sugii

PS179  PULMONARY ARTERIAL HYPERTENSION, CLASSIFICATION CRITERIA
P. Carreira, L. Carmona, B. Joven, MJ. Ruiz Cano, P. Escribano, MA. Gomez-Sanchez
PS180  EPOPROSTENOL RESCUE THERAPY IN SYSTEMIC SCLEROSIS-ASSOCIATED PULMONARY ARTERIAL HYPERTENSION AND IDIOPATHIC PULMONARY ARTERIAL HYPERTENSION

PS181  SEX DISPARITIES IN SURVIVAL OF SYSTEMIC SCLEROSIS-ASSOCIATED PULMONARY ARTERIAL HYPERTENSION AND IDIOPATHIC PULMONARY ARTERIAL HYPERTENSION PATIENTS

PS182  PROGNOSIS OF SYSTEMIC SCLEROSIS (SSC) PATIENTS WITH PULMONARY HYPERTENSION
K. Takagi, Y. Kawaguchi, Y. Ota, T. Higuchi, H. Yamanaka

PS183  SURVIVAL IN SSC-PAH BY SERUM AUTOANTIBODY STATUS
M. Hinchcliff, S. Khanna, J. Lee, O. Almagor, RW. Chang, V. Steen, L. Chung

PS184  THE SIGNIFICANCE OF A ‘NORMAL DLCO’ IN SCLERODERMA (PHAROS) COHORT
T. Frech, M. Murtaugh, L. Shapiro, V. Steen

PS185  UTILITY OF B-TYPE NATRIURETIC PEPTIDES IN THE ASSESSMENT OF PATIENTS WITH SYSTEMIC SCLEROSIS-ASSOCIATED PULMONARY HYPERTENSION IN THE PHAROS REGISTRY
L. Chung, D.E. Furst, S. Li, V.D. Steen, R.T. Zamanian

PS186  THE DIFFERENCES, WHICH SEEM TO BE A PATHOPHYSIOLOGY OF PULMONARY HYPERTENSION, OF CAROTID DOPPLER AND ECHOCARDIOGRAPHIC FINDINGS IN EACH CONNECTIVE TISSUE DISEASE
JH. Choi, SJ. Joo, J. Kim, E.J. Park

PS187  SURVIVAL AT PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION ASSOCIATED WITH SYSTEMIC SCLEROSIS: SINGLE EXPERT CENTRE EXPERIENCE
A. Volkov, N. Yudkina, E. Nikolaeva

PS188  ECHOCARDIOGRAPHIC ALTERATIONS IN A SERIES OF PATIENTS WITH SYSTEMIC SYSTEMIC SCLEROSIS

PS189  ELEVATED SERUM LEVELS OF MACROPHAGE MIGRATION INHIBITORY FACTOR (MIF) AND STEM CELL GROWTH FACTOR BETA (SCGF BETA) IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION (PAH)

PS190  SOME DIFFERENCES BETWEEN CONNECTIVE TISSUE DISEASE-ASSOCIATED AND IDIOPATHIC PULMONARY ARTERIAL HYPERTENSION AT THE TIME OF DIAGNOSIS
M. Luknar, P. Lesny, J. Rovensky, E. Goncalvesova

PS191  PULMONARY ARTERIAL HYPERTENSION IN A CONTEMPORARY DRUG REGISTRY: RESULTS OF THE VOLT STUDY, WITH AN EMPHASIS ON PAH ASSOCIATED WITH CONNECTIVE TISSUE DISEASE
JL. Vachiéry, J. Langley, AJ. Peacock, O. Sitbon, N. Galiè

PS192  PREVALENCE OF PULMONARY HYPERTENSION IN PATIENTS WITH SYSTEMIC SCLEROSIS

PS193  CARDIOTHORACIC RATIO IN CHEST RADIOGRAPHY MAY FORECAST THE OCCURRENCE OF PULMONARY HYPERTENSION IN SYSTEMIC SCLEROSIS
SW. Lee, SW. Yim, SY. Lee, WT. Chung

PS194  EARLY PULMONARY HYPERTENSION AND EARLY PULMONARY FIBROSIS: HOW CAN I TREAT? AND WHO IS THE FIRST?
R. Travassos Jr, E. Freire, C. Burity

PS195  CLINICAL USEFULNESS OF MEASURING RED BLOOD CELL DISTRIBUTION WIDTH (RDW) IN PATIENTS WITH SYSTEMIC SCLEROSIS
C. Varjú, N. Farkas, A. Szabó, V. Lóránd, D.P. Sarlós, T. Minier, Z. Prohászka, L. Czirják
<table>
<thead>
<tr>
<th>PS196</th>
<th>ARRHYTHMIAS AND HEART CONDUCTION DISTURBANCES IN PATIENTS WITH SCLEROSIS SYSTEMIC</th>
<th>R. Cimino, S. Giancotti, C. Pintaudi, S. Mazzuca</th>
</tr>
</thead>
<tbody>
<tr>
<td>PS197</td>
<td>ECHOCARDIOGRAPHY OF THE RIGHT VENTRICLE IN PATIENT WITH SYSTEMIC SCLEROSIS AND RELATED CTD</td>
<td>J. Vymetal, M. Hutyra, A. Smrzova, P. Horak</td>
</tr>
<tr>
<td>PS198</td>
<td>ASYMPTOMATIC CARDIAC INVOLVEMENT IN THAI SYSTEMIC SCLEROSIS: PREVALENCE AND CLINICAL CORRELATION</td>
<td>C. Fooncharoen, B. Pussadhamma, A. Mahakkanukrauh, S. Suwannaroj, R. Nanagara</td>
</tr>
<tr>
<td>PS199</td>
<td>CORRELATION BETWEEN CARDIAC MAGNETIC RESONANCE IMAGING AND ECHOCARDIOGRAPHY IN SYSTEMIC SCLEROSIS</td>
<td>A. Fernández-Codina, C. Simeón, I. Pinal-Fernández, V. Pineda, MN. Pizzi, J. Rodríguez, J. Candell, V. Fonollosa, M. Vilardell</td>
</tr>
<tr>
<td>PS203</td>
<td>CARDIAC VALVE MORPHOLOGY AND LEFT VENTRICULAR FUNCTION IN PATIENTS WITH SYSTEMIC SCLEROSIS (SSC) AND MATCHED POPULATION CONTROLS</td>
<td>A. Nordin, E. Svenungsson, L. Björnådal, K. Jensen-Urstad</td>
</tr>
<tr>
<td>PS206</td>
<td>DESCRIPTIVE STUDY OF CARDIOVASCULAR RISK FACTORS AND ENDOThelial DISFUNCTION IN PATIENTS DIAGNOSED WITH SCLERODERMA AND MIXED CONNECTIVE TISSUE DISEASE</td>
<td>J. Gonzalez Martin, P. García De La Peña Lefebvre, O. Carrion Otero, M. Valero Exposito, S. Rodriguez Rubio, I. Amil Casas, F. Aramburu Muñoz, F. Sainz Gonzalez</td>
</tr>
<tr>
<td>PS207</td>
<td>SCLERODERMA AND MYOCARDIAL INFARCTION: IS NOT FORTUITOUS ASSOCIATION!</td>
<td>N. Slimani, D. Hakem, Z. Benoui, A. Bouchemal, S. Lassouaoui, N. Ouadahi, A. Berrah</td>
</tr>
<tr>
<td>PS208</td>
<td>DATABASE ANALYSIS OF CARDIOVASCULAR RISK FACTORS IN 123 DANISH PATIENTS WITH SYSTEMIC SCLERODERMA</td>
<td>L. Iversen, HC. Ring, M. Mogensen</td>
</tr>
<tr>
<td>PS209</td>
<td>CAN SCORES FROM ENGLISH, FRENCH AND DUTCH VERSIONS OF THE FUNCTIONAL ASSESSMENT OF CHRONIC ILLNESS THERAPY-FATIGUE (FACIT-F) BE POOLED? AN ASSESSMENT OF DIFFERENTIAL ITEM FUNCTIONING</td>
<td>L. Kwakkenbos, L. Willems, M. Baron, M. Hudson, CHM. van den Ende, B. Thombs, CSRG</td>
</tr>
<tr>
<td>PS210</td>
<td>ASSESSMENT OF SENSITIVITY TO CHANGE OF THE DISEASE ACTIVITY SCORE IN SYSTEMIC SCLEROSIS</td>
<td>S. Decuman, K. Melsens, F. De Keyser, Y. Piette, K. De Wilde, D. Elewaut, E. Deschepper, V. Smith</td>
</tr>
</tbody>
</table>
PS211  EXPLORING THE IMPACT OF FOOT DISABILITY IN SYSTEMIC SCLEROSIS
B. Alcacer-Pitarch, A.C. Redmond, M.H. Buch, A.M. Keenan

PS212  TRANSITION OF CARE AND LONG-TERM OUTCOMES OF JUVENILE SYSTEMIC SCLEROSIS DURING ADULTHOOD: RESULTS FROM A FRENCH SINGLE-CENTER CASE-CONTROL STUDY
F. Mauvais, B. Bader-Meunier, A. Berezne, G. Bussone, C. Bodemer, L. Guillemin, P. Quartier, L. Mouthon

PS213  IN SYSTEMIC SCLEROSIS, ANXIETY AND DEPRESSION, ASSESSED BY HOSPITAL ANXIETY DEPRESSION SCALE ARE INDEPENDENTLY ASSOCIATED WITH DISABILITY AND PSYCHOLOGICAL FACTORS
A. Del Rosso, S. Mikhailova, M. Baccini, I. Lupi, M. Matucci Cerinic, S. Maddali Bongi

PS214  SYSTEMIC SCLEROSIS DIAGNOSED IN ELDERLY: A FRENCH RETROSPECTIVE STUDY OF 27 PATIENTS
A. Achille, O. Espitia, F. Perrin, C. Durant, A. Masseau, T. Ponge, J. Connault, A. Néel, MA. Pistorius, MA. Hamidou, C. Agard

PS215  ALEXITHYMIA: UNSPEAKABLE SUFFERING, A PREVALENCE STUDY IN SYSTEMIC SCLEROSIS
M. Vasile, I. Sciarra, K. Stefanantoni, N. Iannace, G. Valesini, V. Riccieri

PS216  ADHERENCE TO RECOMMENDATIONS FOR CERVICAL AND BREAST CANCER SCREENING IN SYSTEMIC SCLEROSIS
P. Caramaschi, R. Vaccari, D. Biasi, C. Caimmi, S. Pieropan, I. Dal Forno, S. Adami

PS217  SURVIVAL PROGNOSTIC FACTORS AND CAUSE OF DEATH IN 213 IRANIAN PATIENTS WITH SYSTEMIC SCLEROSIS
H. Poormoghim, N. Mojtabave, A. Ghorbane, M. Moradi- Lake, S. Almacie, E. Elham Andalib

PS218  OCCUPATIONAL THERAPY IN SYSTEMIC SCLEROSIS. PRELIMINARY RESULTS OF A PILOT STUDY

PS219  A SYSTEMATIC REVIEW ON THE DEVELOPMENT OF DISEASE ACTIVITY INDICES IN SYSTEMIC SCLEROSIS
S. Decuman, K. Melsens, F. De Keyser, V. Smith

PS220  THE VALIDITY OF THE SATISFACTION WITH APPEARANCE SCALE AND THE BRIEF SATISFACTION WITH APPEARANCE SCALE FOR PATIENTS WITH LIMITED AND DIFFUSE SYSTEMIC SCLEROSIS
V. Malcarne, R. Fox, S. Mills, S. Gholizadeh, E. Merz, P. Clements, S. Kafaja, D. Khanna, D. Furst

PS221  FIVE-YEAR SURVIVAL RATE AND PREDICTORS OF DEATH AND DISEASE WORSENING IN A SINGLE-CENTER COHORT OF PATIENTS WITH SYSTEMIC SCLEROSIS

PS222  TARGETING FEAR OF DISEASE PROGRESSION IN RHEUMATIC DISEASES: A CASE STUDY IN SYSTEMIC SCLEROSIS
L. Kwakkenbos, L. Willems, F. van den Hoogen, H. Beenackers, T. Van Helmond, E. Becker, C. Van den Ende

PS223  CORRELATIONS BETWEEN LUNG INVOLVEMENT, QUALITY OF LIFE AND FUNCTIONAL DISABILITY IN PATIENTS WITH LIMITED SYSTEMIC SCLEROSIS
F. Lumetti, L. Barone, C. Alfieri, N. Sverzellati, G. Delsante, A. Ariani

PS224  DEATH IN SYSTEMIC SCLEROSIS
D. Hakem, A. Boudjelida, S. Lassouaoui, M. Ibrir-Khati, S. Medaoud, A. Hamadane, R. Yahiaoui, N. Slimani, N. Ouadahi, A. Berrah, R. Boughrarou, S. Ayat, B. Mansouri

PS225  QUALITY OF LIFE AND PSYCHOSOCIAL ASPECTS IN JUVENILE LOCALIZED SCLERODERMA: A CROSS-SECTIONAL STUDY IN 40 PATIENTS
R. Culpo, M. Ricca, F. Vittadello, G. Sequi, F. Zulian, G. Martini
PS226 MORTALITY IN SSC AND ITS ASSOCIATION WITH CLIMATE CONDITIONS – AN ANALYSIS BASED ON THE EUSTAR DATABASE
M. Langner, K. Scherber, M. Becker, EUSTAR Co-authors, W. Endlicher, G. Riemekasten

PS227 THE IMPACT OF CIGARETTE SMOKING IN SYSTEMIC SCLEROSIS
B. Gundugdu, S. Yolbas, A. Yildirim, S. S. Koca

PS228 CAUSES OF DEATH IN A COHORT OF ARGENTINE PATIENTS WITH SYSTEMIC SCLEROSIS

PS229 MOOD AND ANXIETY DISORDERS IN SYSTEMIC SCLEROSIS PATIENTS

PS230 SCLERODERMIC PATIENTS: AN INTERDISCIPLINARY APPROACH
L. Lisi, E. Plessi, C. Scorollì, R. Meliconi, A. Rapaggi

PS231 SYMPTOMS OF DEPRESSION AND ANXIETY IN CROATIAN PATIENTS WITH SYSTEMIC SCLEROSIS
R. Visevic, S. Rucevic, L. Maricic, V. Prus, J. Milas-Ahic, I. Kovacevic

PS232 PROSPECTIVE ANALYSIS OF THE CLINICAL BURDEN OFLIMITED CUTANEOUS SYSTEMIC SCLEROSIS OVER 12 MONTHS
S. Nihtyanova, V. Ong, C. Denton

PS233 RECOMMENDATIONS FOR FUTURE PATIENT FOCUSED TRIALS ADDRESSING FOOT PAIN IN SYSTEMIC SCLEROSIS
L. Loughrey, H. Collier

PS234 ROLE OF NURSING IN THE PREVENTION OF SKIN ULCERS IN SSC: A PRELIMINARY STUDY
S. Gigli, L. Amanzi, L. Pedrocchi, C. Puccini, A. D’Ascanio, A. Della Rossa, S. Bombardieri

PS235 SSC CLINICAL PROFILE OBSERVED IN A SINGLE INTERNAL MEDICINE DEPARTMENT
D. Hakem, A. Boudjelida, S. Lassouaoui, M. Ibrir, N. Slimani, R. Yahiaoui, Z. Benoui, M. Benidir, S.S. Salah, N. Ouadahi, A. Berrah

PS236 NAILFOLD VIDEOCAPILLAROSCOPY FINDINGS IN SYSTEMIC SCLEROSIS AND PRIMARY RAYNAUD’S PHENOMENON – 12 MONTHS FOLLOW UP STUDY

PS237 UTILITY OF NAILFOLD CAPILLAROSCOPY FOR THE VERY EARLY DIAGNOSIS OF SYSTEMIC SCLEROSIS
KX. Lim, HO. Thein, AHL. Low

PS238 FINGER SKIN VASCULARIZATION IN PATIENTS WITH SYSTEMIC SCLEROSIS – COMPARISON OF ULTRASONOGRAPHY AND CAPILLAROSCOPY
S. Prdanovic, G. Radunovic, M. Zlatanovic, N. Damjanov, N. Gavrilov

PS239 VIRTUAL TOUCH IMAGING AND QUANTIFICATION: A NEW NON-INVASIVE IMAGING METHOD TO MEASURE SKIN STIFFNESS FOR SCLERODERMA

PS240 A STUDY COMPARING VIDEOCAPILLAROSCOPY AND DERMOSCOPY IN THE ASSESSMENT OF NAILFOLD CAPILLARIES IN PATIENTS WITH SYSTEMIC SCLEROSIS–SPECTRUM DISORDERS
M. Hughes, T. Moore, N. O’leary, A. Tracey, H. Ennis, G. Dinsdale, A. Murray, C. Roberts, A. Herrick

PS241 LONGITUDINAL ASSESSMENT OF SCLERODERMA SKIN BY OPTICAL COHERENCE TOMOGRAPHY: PRELIMINARY VALIDATION OF SENSITIVITY TO CHANGE OVER-TIME

PS242 CONE BEAM CT SCAN IN THE MONITORING OF LINEAR SCLERODERMA OF THE FACE: PRELIMINARY RESULTS
C. Di Giovanni, S. Puggina, G. Martini, R. Culpo, F. Zulian

PS243 NON-INVASIVE ASSESSMENT OF SILENT LIVER FIBROSIS IN PATIENTS WITH SYSTEMIC SCLEROSIS
PS244  CHANGES IN THE THICKNESS AND STIFFNESS OF PALMO-PLANTAR SOFT TISSUES IN PEOPLE WITH SYSTEMIC SCLEROSIS
T. Santiago, B. Alcacer-Pitarch, F. Del Galdo F, M.H. Buch, A.C. Redmond

PS245  DO HEATING AND HYDRATION IMPROVE THE QUALITY OF NAILFOLD CAPILLAROSCOPY IMAGES?
T. Moore, J. Wilkinson, I. Maciver, J. Manning, G. Dinsdale, A. Murray, A. Herrick

PS246  VIDEO-CAPILLAROSCOPY OF PERI-CALCINOTIC SKIN INDICATES SPECIFIC FEATURES OF SEVERE MICRO-VASCULOPATHY ASSOCIATED WITH CALCIUM DEPOSITS IN SYSTEMIC SCLEROSIS
L. Loughrey, L.A. Bissell, A. Abignano, EMA. Hensor, M. Cutolo, A. Redmond, F. Del Galdo

PS247  THYMIC FINDINGS BEFORE AND AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION FOR SEVERE SYSTEMIC SCLERODERMA – A RETROSPECTIVE STUDY USING COMPUTED TOMOGRAPHY IN THE PRE- AND POST-TRANSPLANTATION SETTING
J. Henes, L. Kanz, M. Horger

PS248  SCLERODERMA CAPILLAROSCOPIC PATTERNS IN AUTOIMMUNE DISEASES WITH RAYNAUD’S PHENOMENON. REPORT OF 100 PATIENTS
R. Chetouane, F. Rahal, A. Abdessemed, A. Ladjouze-Rezig

PS249  RELATIONSHIP BETWEEN ELASTONOSONOGRAPHY AND CAPILLAROSCOPIC PATTERNS IN SYSTEMIC SCLEROSIS

PS250  MUSCULOSKELETAL ULTRASONOGRAPHY FINDINGS IN SCLERODERMA PATIENTS
N. Inanc, G. Ozen, P. Atagunduz, H. Direskeneli

PS251  INTERSTITIAL LUNG DISEASE ASSOCIATED WITH SINE SCLERODERMA SYSTEMIC SCLEROSIS: A CASE PRESENTATION
I. Velti, C. Bilder, A. Ditaranto, M. Mela, E. Baldessari, J. Caneva

PS252  TOLERABILITY OF INTRAVENOUS PROSTANOID ILOPROST THROUGH ELASTOMERIC PUMP DEVICE IN SCLERODERMA PATIENTS
G. De Marco, P. Tartaro, D. Riccoboni, M. Gazzola, V. Ferri, G. Semenzato, P. Ostuni, R. Marcolongo

PS253  COMPARISON BETWEEN NORMAL INTRAVENOUS INFUSION AND INTRAVENOUS INFUSION THROUGH ELASTOMERIC PUMP OF ILOPROST: EVALUATION OF THE EFFECTIVENESS AND SIDE EFFECTS
E. Bravi, E. Arrigoni, G. Crippa, A. Ariani, C. Concesi

PS254  BIOLOGICAL THERAPY IN SYSTEMIC SCLEROSIS

PS255  ILOPROST AS CYCLIC SIX-DAY PER MONTH. LONG TERM EFFACACY IN SCLERODERMA PATIENTS
R. Foti, G Convero, A Benenati, G Amato, G D’Amico, N Cino, A Farina, M Di Gangi

PS256  TOCILIZUMAB IN SYSTEMIC SCLEROSIS, A SINGLE CENTRE EXPERIENCE
M. Saracco, E. Bellis, G. Rovera, R. Pellerito

PS257  ALTERNATIVE BIOLOGICAL MODEL FOR PRECLINICAL TESTING
I. Levacheva, O. Samsonova, Y. Rubtsof, V. Tkachuk, U. Bakowsky

PS258  MACITENTAN IN THE TREATMENT OF DERMAL FIBROSIS IN PATIENTS AFFECTED BY LIMITED SYSTEMIC SCLEROSIS: IN VITRO EVIDENCES
C. Corallo, G. Pecetti, M. Iglarz, A. Montella, R. Nuti, N. Giordano

PS259  OPTIMIZED FORMULATION OF ENDOGENOUS NEUROPROTECTIVE AGENT
I. Levacheva, E. Kanovalova, T. Fedorova, S. Stvolinskij, V. Koshelev, O. Samsonova, U. Bakowsky

PS260  RAPID RESPONSE OF DIGITAL ULCERS TO BOSENTAN IN SYSTEMIC SCLEROSIS
P. Athanassiou, I. Kostoglou-Athanassiou, D. Basdragianni, A. Papadaki

PS261  SUCCESSFUL TREATMENT OF SYSTEMIC SCLEROSIS DIGITAL ULCERS WITH BOSENTAN
P. Athanassiou, N. Kalaycheva
<table>
<thead>
<tr>
<th>PS262</th>
<th>SAFETY AND EFFECTIVENESS OF MYCOPHENOLATE IN SYSTEMIC SCLEROSIS: A SYSTEMIC REVIEW</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>M.A. Omair, A. Alahmadi, S.R. Johnson</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PS263</th>
<th>TREATMENT OF SYSTEMIC SCLEROSIS WITH TOCILIZUMAB</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>PS264</th>
<th>IDENTIFICATION OF ICD-9 CODES ASSOCIATED WITH SCLERODERMA RENAL CRISIS</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>A. Valenzuela Vergara, A. Yaqub, D. Fiorentino, E. Krishnan, L. Chung</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PS265</th>
<th>INFORMATICS CAN IDENTIFY SYSTEMIC SCLEROSIS PATIENTS AT RISK FOR SCLERODERMA RENAL CRISIS</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>T. Frech, D. Redd, J. Rhiannon, M. Murtaugh, Q. Zeng</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PS266</th>
<th>JUVENILE SCLERODERMA: TREATMENT EXPERIENCE OF A SINGLE ONE CENTER</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>M.K. Osminina, N.A. Geppe, J.O. Kostina, E.Y. Afonina, O.V. Shpitonkova</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PS267</th>
<th>SYSTEMIC SCLEROSIS AT THE CROSSROAD OF POLYAUTOIMMUNITY</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>M. Elhai, J. Avouac, A. Kahan, Y. Allanore</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PS268</th>
<th>CLINICAL AND SEROLOGICAL COMPARATIVE ANALYSIS OF SYSTEMIC SCLEROSIS WITH OR WITHOUT OVERLAP SYNDROMES IN A LARGE BRAZILIAN COHORT</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>PS269</th>
<th>PREVALENCE OF A CHRONIC WIDESPREAD PAIN IN LOCALIZED AND DIFFUSE SYSTEMIC SCLEROSIS PATIENTS</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>S. Stisi, M. Orefice, S. Bellissimo, P. Sarzi-Puttini, F. Atzeni, C. Ricci, A. Batticciotto, G. Biasi, A. Gallo, R. Talotta, M.G. Ferrucci, M. Benucci, V. Di Sabatino</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PS270</th>
<th>SERUM ADROPIN LEVEL AND ENHO EXPRESSION IN SYSTEMIC SCLEROSIS</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>S. Yolbas, M. Kara, M. Yilmaz, S. Aydin, S. S. Koca</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PS271</th>
<th>PREVALENCE AND PREDICTIVE VALUE OF SCLERODERMA–SPECIFIC SERUM AUTOANTIBODIES IN THE GENERAL POPULATION OF A NORTHERN ITALIAN AREA</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>PS272</th>
<th>OSTEOPOROSIS AND FRACTURE RISK IN OUTPATIENTS WITH SYSTEMIC SCLEROSIS</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>V. Codullo, F. Inverardi, S. Breda, L. Bogliolo, F. De Nard, G. Cagnotto, R. Caporali, C. Montecucco</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PS273</th>
<th>ARE THERE DIFFERENCES IN LIMITED SSC ACCORDING TO EXTENSION OF SKIN INVOLVEMENT?</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>PS274</th>
<th>CORRELATION AMONG WHOLE BLOOD VISCOSITY, HEMATOCRIT AND CAPILLAROSCOPIC PATTERNS IN SYSTEMIC SCLEROSIS</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>PS275</th>
<th>AUTOANTIBODIES IN SYSTEMIC SCLEROSIS MAY PREDICT DISEASE SEVERITY, COMPLICATIONS, AND MORTALITY: A SINGLE EUSTAR CENTER (042) EXPERIENCE</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>A. Balbir-Gurman, Y. Braun-Moscovici</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PS276</th>
<th>SSC-OVERLAP SYNDROMES: A DISTINCT CLINICAL SUBGROUP WITH SIGNIFICANT DIFFERENCES IN DISEASE PROGRESSION COMPARED TO LSSC AND DSSC PATIENTS</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>PS277</th>
<th>SYSTEMIC SCLEROSIS-RELATED AUTOANTIBODIES ARE MARKERS OF NEW CLINICAL ASSOCIATIONS IN A COHORT OF 328 BRAZILIAN PATIENTS</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>C.M. Silva, A.B. Bortoluzzo, V.S. Viana, S.G. Pasoto, E.P. Leon, E. Bonfà, P.D. Sampaio-Barros</td>
</tr>
</tbody>
</table>

PS279 HIGH PREVALENCE OF ANTI-THYROID ANTIBODIES IN A NEW ZEALAND COHORT OF PATIENTS WITH SYSTEMIC SCLEROSIS K. Solanki, M. Al-Majmuae, A. Schollum, T. Sole, J. Petrie, D. White, C. Riccioni

PS280 LOW DOSE MODIFIED-RELEASE PREDNISONE TREATMENT AND A THERAPIST-GUIDED EXERCISE PROGRAM IN UNDIFFERENTIATED CONNECTIVE TISSUE DISEASE PATIENTS: OUR 24-MONTH RESULTS C. Marrese, A. Izzo, P. Dell’Aia, G. Sanseverino, E. Bove

PS281 NEUTROPHIL-LYMPHOCYTE AND PLATELET-LYMPHOCYTE RATIOS IN SYSTEMIC SCLEROSIS S. Yolbas, B. Gundugdu, A. Yildirim, S. S. Koca

PS282 COEXISTENCE OF ANTITOPOISOMERASE I AND ANTICENTROMERE ANTIBODIES IN 3 PATIENTS WITH SYSTEMIC SCLEROSIS C. Valette, A. Fauconneau, C. Bordes, C. Combès, C. Dromer, J. Constans, B. Seguy, E. Lazaro, MS. Doutre

PS283 EFFECTS OF ILOPROST ON T-LYMPHOCYTE ACTIVATION PATHWAY IN EARLY SYSTEMIC SCLEROSIS (ESSC) P. Faggioni, A. Gatti, A. Mazzone, A. Sciascera, B. Brando

PS284 DISTRIBUTION OF BODY MASS INDEX AND METABOLIC SYNDROME IN PATIENTS WITH SYSTEMIC SCLEROSIS: STUDY OF A SINGLE ITALIAN CENTRE G. De Luca, SL. Bosello, G. Berardi, M. Rucco, G. Canestrari, M. Correra, A. Capacci, F. Parisi, E. Gremese, G. Ferraccioli


PS286 LEVELS OF VITAMIN D, PTH AND CALCIUM IN PATIENTS WITH SYSTEMIC SCLEROSIS IN LIMITED AND DIFFUSE FORMS M. Salgado, R. Silveira, L. Theilacker, R. Zandonade, S. Francisco, Z. Brito, F. Aguiar, L. D’Almeida, J. Vaz

PS287 BONE MINERAL DENSITY IN PATIENTS WITH SYSTEMIC SCLEROSIS R. Alekperov, A. Smirnov, N. Toroptsova, E. Cheryemurhina

PS288 BONE MICROARCHITECTURE ASSESSMENT BY TRABECULAR BONE SCORE, IN PATIENTS WITH SYSTEMIC SCLEROSIS K. Simic Pasalic, N. Damjanov, G. Marinkovic

PS289 SEXUAL DYSFUNCTION AND LOWER URINARY TRACT SYMPTOMS IN 74 PATIENTS WITH SYSTEMIC SCLEROSIS K. Sanchez Barrueto, P. Denys, F. Giuliani, C. Palazzo, A. Berezne, H. Abid, F. Rannou, S. Poiraudeau, L. Mouthon

PS290 ANTI-NUCLEAR AUTOANTIBODIES IN 200 IRANIAN PATIENTS WITH SYSTEMIC SCLEROSIS: CORRELATION WITH CHARACTERISTIC CLINICAL FEATURES H. Poormoghim, N. Mojtabavi, A.s. Ghorbannia, M. Moradi-Lake, B. Asadifar, M. Ghelman, S. Almacie, E. Andalib

PS291 SEVERITY OF NAILFOLD CAPILLARY MICROSCOPY CORRELATE WITH BONE MINERAL DENSITOMETRY BY ULTRASONOGRAPHY AND RODNAN SKIN SCORE IN SSC PATIENTS R. Cimino, C. Pintaudi, S. Giancotti, S. Mazzuca

PS292 CALCINOSIS PREFERENTIALLY AFFECTS THE THUMB COMPARED TO OTHER FINGERS IN PATIENTS WITH SYSTEMIC SCLEROSIS R. Gauhar, J. Wilkinson, J. Harris, J. Manning, A. Herrick

PS293 SMOKING AND ITS EFFECT ON SKIN OF PATIENTS WITH SYSTEMIC SCLEROSIS R. López Martinez, J. Pretini, D. Vera Alarcón, A. Villacreses Arteaga, V. Cosentino, S. Montoya, E. Kerzberg
PS294  CORRELATION BETWEEN CHRONIC WIDESPREAD PAIN OR FIBROMYALGIA AND ACTH AXIS ALTERATIONS IN PATIENTS WITH LOCALISED AND DIFFUSE SYSTEMIC SCLEROSIS
R. Talotta, F. Matucci, M. Benucci, F. Li Gobbi, M. Manfredi, M. Infantino, G. Baldi, T. Vago, S. Stisi, P. Sarzi-Puttini, F. Atzeni

PS295  INFLUENCE OF GENDER, ETHNICITY AND AGE AT ONSET IN THE CLINICAL PRESENTATION OF SYSTEMIC SCLEROSIS IN A LARGE BRAZILIAN COHORT OF 1017 PATIENTS

PS296  ARTERIAL STIFFNESS IN SSC PATIENTS- A SINGLE CENTRE EXPERIENCE
A. Petcu, M. Rinzis, A. Albu, S. Rednic

PS297  JUVENILE SCLERODERMA INTERNATIONAL NETWORK (JUSINET) DATABASE: A RELIABLE INSTRUMENT FOR CLINICAL RESEARCH IN JUVENILE SCLERODERMA SYNDROMES

PS298  MODIFIED RODNAN SKIN SCORE: A NEW TECHNOLOGICAL APPROACH
S. Parisi, M. Scarati, M. Priora, M. Bruzzone, E. Fusaro

PS299  SIGNIFICANCE OF IGG LEVELS IN THE WAIKATO HOSPITAL SYSTEMIC SCLEROSIS COHORT
K. Ip, A. Schollum, J. Petrie, T. Sole, D. White, K. Solanki

PS300  SEVERE VITAMIN D DEFICIENCY IN SYSTEMIC SCLEROSIS
F. Lumetti, D. Giuggioli, A. Spinella, F. Campomori, A. Manfredi, C. Ferri

PS301  ENVIRONMENTAL FACTORS AND INDUCTION OF SYSTEMIC SCLEROSIS: ANALYSIS OF 211 CONSECUTIVE PATIENTS
P. Sampaio-Barros, L. Aquila, A.C. Medeiros, L. Seguro, D. Andrade

PS302  UTILITY OF THE 6 MINUTE WALKING TEST IN SYSTEMIC SCLEROSIS, EXPERIENCE FROM 20 CROATIAN PATIENTS
R. Visevic, L. Maricic, S. Rucevic, V. Prus, J. Milas-Ahic, I. Kovacevic

PS303  PARTICULARITIES OF SCLERODERMA IN MALE PATIENTS
S. Lassouaoui, D. Hakem, N. Ouadahi, A. Boudelida, A. Berrah

PS304  CLINICAL UTILITY OF SALT & PEPPER SKIN CHANGES IN THE WAIKATO HOSPITAL SYSTEMIC SCLEROSIS COHORT
K. Solanki, C. Hor, A. Schollum, R. Campbell, M. Empson, T. Sole, J. Petrie, D. White

PS305  MUSCULAR INVOLVEMENT IN PATIENTS WITH SYSTEMIC SCLEROSIS: MYOSITIS RELATED TO SSC OR TO OTHER AUTOIMMUNE DISEASE?
T. Ben Salem, M. Maiza, A. Hamzaoui, M. Khanfir, I. Ben Ghorbel, M. Lamloum, MH. Houman

PS306  PERIPHERAL NEUROPATHY IN SYSTEMIC SCLEROSIS PATIENTS: A PILOT STUDY
M. Radic, D. Vucina, D. Martinovic Kaliterna, J. Radic, D. Perkovic

PS307  PROTECTIVE EFFECTS OF SUPPLEMENTATION WITH 25-HYDROXYVITAMIN D AND AN INDIVIDUALIZED REHABILITATION PROGRAM IN SYSTEMIC SCLEROSIS PATIENTS: OUR 2-YEAR EXPERIENCE
C. Marrrese, A. Izzo, P. Dell’Aia, E. Bove, E. Grimaldi, C. Riccioni

PS308  JOINT INVOLVEMENT IN SYSTEMIC SCLEROSIS AND ITS RELATIONSHIP WITH AUTOANTIBODY TO ANTI-CYCCLIC CITRULLINATED PEPTIDE

PS309  22 YEARS EXPERIENCE OF PATIENTS WITH SYSTEMIC SCLEROSIS ON HOME PARENTERAL NUTRITION
E. Harrison, A.L. Herrick, J.T. McLaughlin, S. Lal
PS310  ESOPHAGEAL INVOLVEMENT IN SYSTEMIC SCLEROSIS: CLINICAL CORRELATIONS
M. Lara, M. Rivero, N. Aldabe, R. Ramos, G. Salis, F. Zazzetti, J. Romero, M. Khoury, L. Colombato, J. Barreira

PS311  COMPARISON OF MID UPPER ARM ANTHROPOMETRY TO BODY MASS INDEX IN PATIENTS WITH SYSTEMIC SCLEROSIS
E. Harrison, A.L. Herrick, J.T. McLaughlin, S. Lal

PS312  OBESITY: A NEW ASPETC OF MALNUTRITION IN SYSTEMIC SCLEROSIS
R. Carignola, V. Data, E. Montabone

PS313  ASSESSMENT OF VALIDITY OF GASTROINTESTINAL MOTILITY PROCEDURES USED IN SYSTEMIC SCLEROSIS, BASED ON OMERACT CRITERIA
Y. Braun-Moscovici, M. Braun, D. Khanna, A. Balbir-Gurman, D.E. Furst

PS314  ESOPHAGEAL ABNORMALITIES IN VERY EARLY SYSTEMIC SCLEROSIS. A CASE SERIES
I. Veltri, D. Bruno, M. Mela, A. Ditaranto, E. Baldessari, C. Bilder

PS315  SMALL INTESTINAL BACTERIAL OVERGROWTH IN PATIENTS WITH SYSTEMIC SCLEROSIS, CLINICAL DATA RELEVANCE
T. Soukup, J. Cyrany, M. Kopacova, I. Tacheci, J. Bures

PS316  SYSTEMATIC EVALUATION OF ESOPHAGEAL AND ANORECTAL DAMAGE IN SYSTEMIC SCLEROSIS: PRELIMINARY RESULTS

PS317  TRANSLATION, CROSS-CULTURAL ADAPTATION, AND VALIDATION OF THE UNIVERSITY OF CALIFORNIA, LOS ANGELES SCLERODERMA CLINICAL TRIAL CONSORTIUM GASTROINTESTINAL TRACT INSTRUMENT 2.0 INTO THE DUTCH LANGUAGE
J. Meijs, D. Pors, T. Vliet-Vlieland, T. Huizinga, A. Schouffoer

PS318  GIT MANIFESTATIONS OF SYSTEMIC SCLEROSIS AS THE MOST FREQUENT. IS IT THE MOST IRRITANT TOO?
N. Fathi, H. Imam, D. Hammady, M. Abdiaziz, H. Abozaid

PS319  CHARACTERIZATION OF SYSTEMIC SCLEROSIS PATIENTS FOLLOWED IN A SYSTEMIC IMMUNE MEDIATED DISEASES CLINIC - 4 YEAR RETROSPECTIVE ANALYSIS
J. Caetano, F. Paula, M. Amaral, S. Oliveira, J. Delgado Alves

PS320  CHARACTERIZATION OF INTERSTITIAL LUNG DISEASE IN A COHORT OF SYSTEMIC SCLEROSIS PATIENTS - 4 YEAR FOLLOW-UP DATA
F. Paula, J. Caetano, M. Amaral, S. Oliveira, J. Delgado Alves

PS321  THE TYROSINE KINASE INHIBITOR DASATINIB EFFICIENTLY BLOCKS PDGF-INDUCED ORBITAL FIBROBLAST ACTIVATION: A POTENTIAL NOVEL THERAPEUTIC AGENT IN FIBROTIC DISEASE?
S. Virakul, V.A.S.H. Dalm, D. Paridaens, W.A. van den Bosch, N. Hirankarn, P.M. Van Hagen, W.A. Dik

PS322  UPDATE ON THE JUVENILE SYSTEMIC SCLEROSIS INCEPTION COHORT. WWW.JUVENILESCLERODERMA.COM

PS323  SYSTEMIC SCLEROSIS IN OVERLAP WITH RHEUMATOID ARTHRITIS: A RATHER FREQUENT ASSOCIATION IN SCLERODERMA PATIENTS
C. Mihai, R. Dobrota, A. Soare, AM. Gherghe, DL. Constantin, M. Gorga, RC. Ionitescu, M. Bojinca, V. Stoica

PS324  EVOLUTION OF SYSTEMIC SCLEROSIS OVERLAP SYNDROME
O. Desinova, M. Starovoytova, L. Ananieva, N. Guseva

PS325  ASSOCIATION BETWEEN SYSTEMIC SCLEROSIS AND SJÖGREN’S SYNDROME
T. Ben Salem, A. El Ouni, M. Khanfir, A. Hamzaoui, M. Lamloum, I. Ben Ghorbel, MH. Houman
PS326 SJOGERNS SYNDROME IN SYSTEMIC SCLEROSIS
S. Agachi, L. Groppa, S. Popa

PS327 EFFECT OF AMBRISENTAN ON DIGITAL ULCERS IN SYSTEMIC SCLEROSIS: A CASE REPORT
V. Tomaselli, D. D’Ambrosio, L. Massarelli, D. Roccatello

PS328 IMPROVEMENT OF PULMONARY FUNCTION IN A PATIENT WITH INTERSTITIAL LUNG DISEASE SECONDARY TO SYSTEMIC SCLEROSIS AFTER TREATMENT WITH TOCILIZUMAB
A. Severino, B. Vigone, L. Beretta

PS329 CATASTROPHIC ANTIPHOSPHOLIPID SYNDROME AND SYSTEMIC SCLEROSIS- A RARE ASSOCIATION
A. Petcu, M. Rinzis, S. Rednic

PS330 SYSTEMIC SCLEROSIS WITH SYSTEMIC LYMPHADENOPATHY COMPLICATED BY ADENOCARCINOMA PROSTATE AND TUBERCULOSIS
E. Morgiel, M. Madej, P. Wiland

PS331 SUCCESSFUL TREATMENT OF MEDICALLY REFERATORY SCLERODERMA DIGITAL GANGRENE WITH LONGTERM CONTINUOUS BRACHIAL PLEXUS BLOCK

PS332 A CASE OF LONG-STANDING LIMITED CUTANEOUS SCLERODERMA WITH CHRONIC INFECTION – DIAGNOSTIC CHALLENGES
S. Lambova, L. Sapundzhiev

PS333 COMPLEX PATHOPHYSIOLOGY OF PULMONARY HYPERTENSION ASSOCIATED WITH SYSTEMIC SCLEROSIS: MERITS AND DEMERITS OF AGGRESSIVE TREATMENT WITH PULMONARY VASODILATORS
M. Kuwana, Y. Tamura

PS334 COEXISTENCE OF SYSTEMIC SCLEROSIS AND SARCOIDOSIS: A CASE REPORT
S. Kobak, F. Sever, O. Sivrikoz

PS335 RENAL THROMBOTIC MICROANGIOPATHY TRIGGERED BY LUNG CANCER IN LIMITED SSC-A CASE REPORT
T. Kise, N. Yokogawa, K. Shimada, S. Sugii

PS336 PRIMITIVE HEART DISEASES IN SYSTEMIC SCLEROSIS : REVIEW OF 05 CASES
D. Hakem, M. Ibrir, S. Lassouaoui, R. Boughrarou, S. Ayat, N. Ouadahi, B. Mansouri, A. Berrah

PS337 DIGITAL NECROSIS IN SYSTEMIC SCLEROSIS NOT ONLY A MICROVASCULAR DISEASE: A CASE REPORT
A. Spinella, D. Giuggioli, A. Manfredi, F. Lumetti, F. Campomori, C. Ferri

PS338 SCLERODERMA MODEL OF CARE – TEAM MEETINGS
B. Gemmell, C. Page, H. O’Sullivan

PS339 A PARTICULAR CASE OF SEVERE SYSTEMIC SCLEROSIS, PROCEEDED BY BULLOUS MANIFESTATIONS IN APPARENTLY QUIESCENT SCLERODERMA
R. Colia, A. Marucci, V. Di Bello, A. Gaudio, F.P. Cantatore

PS340 THYROID DYSORDERS IN PATIENTS WITH SYSTEMIC SCLEROSIS: BIOCHEMICAL AND SONOGRAPHIC CHARACTERISTICS
P. Rotman-Pikielny, M. Werner, Y. Levy

PS341 EXERCISE TRAINING IN SYSTEMIC SCLEROSIS – FIVE SSC PATIENTS FINISHED THE BERLIN MARATHON
M. Buslau, M. Müller, A. Gösele, Th. Ettlin

PS342 SYSTEMIC SCLEROSIS ASSOCIATED TO SYSTEMIC LUPUS ERYTHEMATOSUS

PS343 BK VIRUS ASSOCIATED HAEMORRHAGIC CYSTITIS IN A SCLERODERMA PATIENT AFTER CYCLOPHOSPHAMIDE THERAPY
A. Belotti Masserini, PL. Colombelli, S. Panza, G. Dognini, F. Cagnoni, C. Mastaglio, M. Destro
PS344  SPECIFIC ATROPHY OF THE VOCAL FOLD DURING SCLERODERMA: UNDERESTIMED IMPACT ON QUALITY OF LIFE, ABOUT 2 CASES
P. Bélénotti, A. Lagier, A. Benyamine, B. Granel, J. Serratrice, A. Giovanni, PJ. Weiller

PS345  RITUXIMAB TREATMENT IN DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS: A CASE REPORT

PS346  SPARING EFFECT OF HEMIPLEGIA ON SCLERODERMA-LIKE MICROVASCULAR INVOLVEMENT AND SKIN FIBROSIS: A CASE REPORT
N. Ughi, F. Ingegnoli, R. Gualtierotti, S. Zeni

PS347  A RARE CASE OF CHRONIC EFFUSIVE-CONSTRUCTIVE PERICARDITIS IN LIMITED CUTANEOUS SYSTEMIC SCLEROSIS
K. Solanki, S. Pasupati, I. Ternouth

PS348  A RARE PRESENTATION OF SCLERODERMA RENAL CRISIS FOLLOWING SILICONE BREAST IMPLANT RUPTURE
G. Al Aranji, D. White, K. Solanki

PS349  A CASE OF SYSTEMIC SCLEROSIS PATIENT THAT HAD SEVERE HYPOTENSION WITH ACUTE RENAL FAILURE DUE TO THE SILDENAFIL
S. Nah, S. Jung, J. Jeon, H. Kim

PS350  SYSTEMIC SCLEROSIS WITH EXTENT NECROSIS AND LOST OF PART OF THE FOOT– A CASE REPORT

PS351  AN ALTERNATIVE APPROACH TO THE MANAGEMENT OF A PATIENT WITH SSC-MYOSITIS ASSOCIATED WITH DYSPHAGIA
M. Hughes, E. Harrison, P. Paine, A. Herrick

PS352  A MULTI-DISCIPLINARY APPROACH TO THE MANAGEMENT OF A PATIENT WITH RAPIDLY PROGRESSIVE SSC, SEVERE GASTROINTESTINAL INVOLVEMENT AND MALNUTRITION
M. Hughes, E. Harrison, P. Paine, A. Herrick

PS353  ANGIOSARCOMA OF THE SCALP IN A PATIENT WITH SYSTEMIC SCLEROSIS
Y. Fujisawa, Y. Nakamura, Y. Kawachi, M. Fujimoto

PS354  WHEN DOES SYSTEMIC SCLEROSIS IN CHILDHOOD REALLY START? AN ORIGINAL CASE REPORT
C. Culpo, M. Cappella, G. Martini, F. Zulian

PS355  A RARE PRESENTATION OF NECK PAIN WITH RADICULOPATHY IN DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS
K. Solanki, W. Chang, A. Schollum, Z. Hussain

PS356  CONVINCING EFFECT OF BOTULINUM TOXIN A TO TREATMENT RESISTANT DIGITAL ULCERS ON TOES IN A PATIENT WITH SYSTEMIC SCLEROSIS. A CASE
J. Baumgartner-Nielsen, A. Braae Olesen
Congress Venue
Ergife Palace Hotel & Conference Center
Via Aurelia 619 - 00165 Rome, Italy
Telephone: +39 06 66441
www.ergifepalacehotel.com

How to reach the Congress Venue

By car
From motorway A1, A12 or A24, take the “Grande Raccordo Anulare”, exit 1 “Aurelia” in direction “Roma Centro Vaticano”. Then follow Via Aurelia until number 619.

By train/subway
From railway station “Termini” take the subway - line A, direction “Battistini” until “Cornelia” stop. Follow exit “Piazza Idroscalo” and then “Via Aurelia”. Then take the bus no. 246 and get off after two stops.

By plane
From the Rome international airport “Leonardo da Vinci” in Fiumicino, take the train “Leonardo Express” until the railway station “Termini” and then follow the indications here above.

Organizing Secretariat
AIM Group International
Florence Office
Viale G. Mazzini, 70 - 50132 Florence
tel 055 233881 - fax 055 2480246
ssc2012@aimgroup.eu
www.sscworldcongress.org

Onsite the Registration Desk will be open for participants at the following times: Thursday, February 6 from 11:30 to 20:00, Friday, February 7 from 07:30 to 18:00 and Saturday, February 8 from 07:30 to 13:30

<table>
<thead>
<tr>
<th>REGISTRATION FEE (VAT incl.)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Physicians</td>
</tr>
<tr>
<td>PhD/Young Investigators*/Fellows</td>
</tr>
<tr>
<td>HP</td>
</tr>
<tr>
<td>Medical Students**</td>
</tr>
<tr>
<td>Patients</td>
</tr>
</tbody>
</table>

* For young doctors under 30 years of age. Copy of the ID or passport is requested.
** These individuals must include a letter from their program director, chief of service or faculty advisor to be eligible for reduced fees.

Registration fees include:
Congress kit, access to the scientific sessions, admission to the exhibition and poster area, certificate of attendance, coffee breaks and working lunch as indicated in the programme, abstracts book in the USB pendrive and online subscription for one year to “Clinical and Experimental Rheumatology – Clinical and Experimental Scleroderma”.

Registration fee for patients includes:
Congress kit, access to the Opening Ceremony of the medical congress, scientific sessions of the patient congress only, coffee breaks and working lunch as indicated in the patient program.
**Congress badges**
Each participant may collect the badge at the registration desk. Participants are kindly requested to wear their badge during all congress activities and social events.

- No colour: Participant
- Red colour: Speakers and Chairpersons
- Yellow colour: Exhibitors and Sponsors
- Blue colour: Patients

**Internet connection**
Free wi-fi connection is available in all congress spaces. No password is requested.

**Language**
The official language is English.

**Catering**

**Coffee breaks**
Coffee breaks will be organized in the exhibition area, Level -2 during the following times:
- *Friday, February 7* from 10:10 to 10:30 and from 16:40 to 16:55
- *Saturday, February 8* from 10:30 to 10:45

**Lunch**
A standing buffet lunch will be offered to all registered participants on *Friday, February 7* from 13:30 to 14:30 in the exhibition area, level -2.

**Certificate of Attendance**
Certificates of attendance will be available on request starting from *Saturday, February 8* at the Registration desk.

**Exhibition**
An exhibition will be open in the following days at level -2:
- *Thursday, February 6* from 15:00 to 19:00
- *Friday, February 7* from 08:30 to 18:00
- *Saturday, February 8* from 08:30 to 13:30.

**Social Programme**

**Welcome Cocktail – Thursday, February 6**
A light welcome cocktail will be held after the Opening Ceremony in the lobby of the hotel, in the bar area for all registered participants.

**Congress Dinner – Friday, February 7**
A seated Congress Dinner will be held at Palazzo Brancaccio in Viale del Monte Oppio 7.
Transfer by bus will be provided from the hotel Ergife at 19:30. The dinner will start at 20:00. Limited number of participants. Reservations are accepted on a “first come first served” basis.
Remaining tickets will be sold at the “New registration” desk until *Friday, February 7* at 10:00.
Abstract Sessions
Selected papers will be orally presented by the Authors. Authors have the time indicated in the programme including the discussion.

Poster Session & Poster tours

Posters Session
Poster session will take place in the Poster Area at the ground floor. Authors have been given a number and must be fixed on the poster board marked with the same number. Posters must be hanged on Friday, February 7 from 08:00 to 09:00 for display and removed within 13:30 on Saturday, February 8. Poster size must be cm. 90 (width) x cm. 150 (height) and the format must be VERTICAL.

Poster tours
Tours will take place in the Poster Area at the ground floor on Friday, February 7 from 11:00 to 12:00. Participants who made the pre-registration to the poster tours are kindly requested to gather at 10.50 in front of the entrance of the Poster Area, in the meeting point indicated with the number of the tour, to join their leader and start at 11:00 the tour. Posters selected for the poster tours are indicated in the scientific program.

For both poster sessions and poster tours on Friday, February 7 authors are kindly asked to stand by their poster at 11:00 either for discussion with delegates or for discussion during the poster tour. Saturday, February 8 posters can be left in the Poster Area for the whole morning until 13:30.

Meet the Professors session
Meet the Professors sessions will be organized on Saturday, February 8 from 08:00 to 09:00 (see the scientific program) for young practicing physicians only, for a maximum of 15 participants each, on first come, first served basis. Remaining places can be booked at the “New registration” desk.

Slide Center
The Slide Center is available in the GERASA ROOM at level -2. Speakers are requested to load their slides in the Slide Center at least three hours before their presentation (or, if their session starts at 8:00, by 18:00 on the previous day). The opening hours of the slide center are: Thursday, February 6, from 12:00 to 19:30, Friday, February 7 from 07:30 to 17:00 and Saturday, February 8, from 07:30 to 13:00.

Abstract book
The abstracts of the oral presentations and posters are included in the USB pendrive in the congress bag.
The Congress Organisers gratefully acknowledge support received from all exhibitors and the following sponsors:

Platinum Sponsor

Gold Sponsor

Silver Sponsor

Bronze Sponsors

The patient congress is supported by:
Organizing Secretariat

AIM Group International
Florence Office
Viale G. Mazzini, 70
50132 Florence, Italy
ph. +39 055 233881
fax +39 055 2480246
ssc2014@aimgroup.eu
www.sscworldcongress.org